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ABSTRACT 
GM2 gangliosidoses are a family of lysosomal storage disorders that include 
both Tay-Sachs and Sandhoff diseases.  These disorders result from deficiencies in 
the lysosomal enzyme β-N-acetylhexosaminidase (HexA). Impairment of HexA leads 
to accumulation of its substrate, GM2 ganglioside, in cells resulting in cellular 
dysfunction and death. There is currently no treatment for GM2 gangliosidoses. 
Patients primarily present with neurological dysfunction and degeneration. Here we 
developed a central nervous system gene therapy through direct injection that leads 
to long-term survival in the Sandhoff disease mouse model. We deliver an equal 
mixture of AAVrh8 vectors that encode for the two subunits (α and β) of HexA into 
the thalami and lateral ventricle. This strategy has also been shown to be safe and 
effective in treating the cat model of Sandhoff disease. We tested the feasibility and 
safety of this therapy in non-human primates, which unexpectedly lead to 
neurotoxicity in the thalami. We hypothesized that toxicity was due to high 
overexpression of HexA, which dose reduction of vector could not compensate for. 
In order to maintain AAV dose, and therefore widespread HexA distribution in the 
brain, six new vector designs were screened for toxicity in nude mice.  The top three 
vectors that showed reduction of HexA expression with low toxicity were chosen and 
tested for safety in non-human primates. A final formulation was chosen from the 
primate screen that showed overexpression of HexA with minimal to no toxicity. 
Therapeutic efficacy studies were performed in Sandhoff disease mice to define the 
minimum effective dose. 
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PREFACE 
Most of the work presented here was completed in Dr. Miguel Sena-
Esteves’ Laboratory at the University of Massachusetts Medical School under his 
supervision. In addition, Dr. Douglas R. Martin at Auburn University was a 
consultant on this project. 
Chapter I 
Some parts of the Introduction are based on a book chapter that I wrote 
and was published in Gene Delivery and Therapy for Neurological Disorders.1 
Chapter II 
The Sandhoff disease (SD) mice in Chapter II were housed at Boston 
College and surgeries and tissue collection were performed there.  Hannah 
Rockwell, in the Laboratory of Thomas Seyfried at Boston College, was 
responsible for maintaining the SD mouse colony, experimental animals, and 
their behavioral testing. I performed all surgeries with the assistance of Miguel 
Sena-Esteves. I performed all necropsies, tissue, and data analysis. Stanley 
Leroy created and packaged the AAVrh8-mHexα/β vectors in the Laboratory of 
Miguel Sena-Esteves. The University of Massachusetts Medical School Vector 
Core packaged the AAV8-TBG-mHexβ vector that I cloned. I extracted all tissue 
and prepared samples for LC-MS/MS analysis of GM2 ganglioside content. 
Samples were run at the University of Massachusetts Medical School Proteomics 
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and Mass Spectrometry Facility and analyzed by myself. 
Chapter III 
Chapter III has been submitted to Human Gene Therapy and is currently 
under review. I am the first author on this article, and completed the first stage of 
manuscript composition. Dr. Sena-Esteves and co-authors edited the manuscript 
into its final form. Dr. Sena-Esteves is the corresponding author. Dwijit 
GuhaSarkar originally cloned the cynomolgus macaque HEXA and HEXB cDNA. 
Stacy Maitland packaged the final AAVrh8-CBA-Hexα/β-WPREmut6rATG vectors 
and measured their endotoxin levels. The Core Electron Microscopy Facility at 
the University of Massachusetts Medical School analyzed vectors for empty 
capsids with electron microscopy. The University of Massachusetts Medical 
School Vector Core screened primates for neutralizing antibodies against 
AAVrh8. Drs. Wael Asaad and Churl-Su Kwon performed primate surgeries at 
the New England Center for Stroke Research in the University of Massachusetts 
Medical School. Drs. Imramsjah M.J. van der Bom and Anna Luisa Kühn also 
performed imaging there under the supervision of Dr. Matthew Gounis. Nina 
Bishop from Animal Medicine at the University of Massachusetts Medical School 
assisted with primate surgeries and neurological monitoring. Elizabeth Curran 
and Nilsa Silva performed monkey necropsies at the New England Primate 
Research Center (NEPRC). Neuropathology (H&E, CD68, CD3, CD20) was 
stained at NEPRC and assessed by Drs. Andrew Miller and Keiko Petrosky 
	 xv 
under the supervision of Dr. Susan Westmoreland. Dr. Allison Bradbury, in the 
Laboratory of Dr. Douglas R. Martin at Auburn University, measured serum 
antibody titers towards AAVrh8 and human Hexα (Figure 3.2). I diluted vector for 
injection, performed neurological assessments, and all other tissue and data 
analysis. 
Chapter IV 
The AAVrh8-cmHexα/β vectors in Chapter IV were cloned with the 
assistance of Stacy Maitland and purified by myself. Elena Balkanska-Sinclair 
assisted me with nude mouse surgeries and tissue collection and also performed 
in vitro enzymatic assays on CNS tissue (Figures 4.2 & 4.3). Nude mouse tissue 
embedding, H&E, Iba-1, and GFAP staining was performed by the University of 
Massachusetts Medical School Morphology Core Facility. Drs. Wael Asaad, Julie 
Pilitsis, and Miguel Sena-Esteves performed primate surgeries at the New 
England Center for Stroke Research in the University of Massachusetts Medical 
School. Dr. Kajo Van der Marel performed imaging there under the supervision of 
Dr. Matthew Gounis. Nina Bishop and Dr. Rosemary Santos from Animal 
Medicine at the University of Massachusetts Medical School assisted with 
primate surgeries and neurological monitoring. Elizabeth Curran performed 
monkey necropsies at NEPRC. Neuropathology of monkey thalamus (H&E) was 
stained by the University of Massachusetts Medical School Morphology Core 
Facility and assessed by Drs. Keiko Petrosky and Elizabeth Hutto under the 
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supervision of Dr. Sheila M. Cummings Macri at NEPRC. Jennifer Ferreira, in the 
Laboratory of Dr. Miguel Sena-Esteves, assisted me with tissue biopsy collection 
for in vitro enzymatic assays in Table 4.2. AAVrh8-CB-CI-mHexα/β vectors were 
cloned and packaged by myself and I performed all experiments, tissue, and data 
analysis using this vector on SD mice. I extracted all tissue and prepared 
samples for LC-MS/MS analysis of GM2 ganglioside content. Samples were run 
at the University of Massachusetts Medical School Proteomics and Mass 
Spectrometry Facility and analyzed by myself. I performed all other experiments 
and/or tissue and data analysis as well as manuscript preparations.
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CHAPTER I – INTRODUCTION 
Lysosomal storage disorders 
Lysosomal storage disorders (LSDs) are caused by a defective enzyme or 
cofactor that performs its function ultimately in the lysosome. Over 40 lysosomal 
enzymes work in tandem to break specific covalent bonds sequentially and 
degrade cellular metabolites to their basic components (amino acids, lipids, and 
sugars). A lysosomal enzyme defect blocks one or multiple metabolic pathways, 
leading to accumulation of specific substrates such as glycogen, 
mucopolysaccharides (MPS), glycoproteins, and sphingolipids.2 Cellular 
dysfunction and death result from different molecular mechanisms such as direct 
toxicity of a substrate or dysregulation of intracellular calcium homeostasis (e.g., 
GM1-gangliosidosis and psychosine in Krabbe disease).3-5 Most of the 
monogenic LSDs are inherited in an autosomal recessive manner, though 
notable exceptions include X-linked disorders such as Hunter syndrome (MPS II), 
Danon disease, and Fabry disease. There are at least 50 LSDs, most often 
caused by a deficiency or complete loss of a soluble lysosomal enzyme.6 Less 
commonly, LSDs may be caused by defective accessory or lysosomal membrane 
proteins. For example, the AB variant of GM2 gangliosidoses is due to the loss of 
the GM2 activator protein, which is necessary for β-hexosaminidase to break 
down GM2 ganglioside.2, 7 Niemann-Pick disease type C (NPC) is caused by 
mutations in the NPC1 gene, which encodes a lysosomal membrane transporter. 
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Dysfunction of the transport system leads to storage of free cholesterol and other 
glycolipids in lysosomes.3, 4, 8 
Taken together, the incidence of all LSDs is estimated to be 1 in 8,000 live 
births. Though infants and children are most commonly and severely affected, 
later-onset forms of LSDs have a milder phenotype with a spectrum of 
symptoms.6, 9 This is thought to result from mutations where enzymes retain 
some residual activity, unlike in the infantile associated mutations where there is 
no residual activity. Due to universal necessity of functional lysosomes, LSDs 
present clinically with multiple organ pathology, though severe neurological 
symptoms often overshadow peripheral disease manifestations.2, 6 Recent 
studies have now documented mild neurological disease in many LSDs once 
thought to be non-neuropathic, such as Pompe disease.10 
 
GM2 gangliosidoses 
Tay-Sachs Disease (TSD) and Sandhoff Disease (SD) belong to a family 
of lysosomal storage disorders (LSDs) known as GM2 gangliosidoses. The 
incidences of Tay-Sachs disease is 1 in 222,000 live births while Sandhoff 
disease is 1 in 422,000 live births. The carrier frequency for Tay-Sachs disease 
is 1 in 224 while Sandhoff disease is 1 in 310 people.9 The carrier frequency and 
incidence of Tay-Sachs disease is about one hundred times higher in the 
Ashkenazi Jewish population.11 Both TSD and SD result from a deficiency in the 
lysosomal enzyme β-N-acetylhexosaminidase (Hex, hexosaminidase, EC 
	 3 
3.2.1.52), which breaks down the cellular metabolite GM2 ganglioside into GM3 
ganglioside by hydrolyzing the terminal N-acetyl galactosamine residue in the 
lysosome. HexA is a heterodimer of α- and β-subunits, which are encoded by the 
HEXA and HEXB genes, respectively. TSD results from mutations in HEXA (Chr 
15q23-24) while SD results from mutations in HEXB (Chr 5q13). Other isozymes 
of Hex include HexB, a β/β dimer, and HexS, a α/α dimer, neither of which can 
cleave GM2 ganglioside in humans.12 However, HexB participates in the 
catabolic pathway in other species, notably mice.13 As with most lysosomal 
glycosidases, Hex isozymes can cleave a broad spectrum of substrates with the 
terminal non-reducing sugars, GlcNAc or GalNAc, in β-linkage.12 The GM2 
activator protein, encoded by the GM2AP gene, is also required to transfer GM2 
ganglioside to HexA for cleavage. Mutations in GM2AP (Chr 5q32-33), although 
rare, lead to the AB variant of GM2 gangliosidoses (Figure 1.1). HexA deficiency 
leads to accumulation of GM2 ganglioside in the lysosome causing dysfunction 
and eventual cell death. GM2 gangliosidoses primarily affect the central nervous 
system (CNS) leading to progressive neuronal degeneration.12 Other peripheral 
pathology has been unveiled after correction of the CNS phenotype, such as 
distension of the urinary bladder and fecal impaction in Sandhoff disease cats 
and mice.14, 15 In addition, two brothers with late-onset Sandhoff disease also 
presented with dysautonomic achalasia.16 
	 4 
 
Figure 1.1 Genetics of GM2 Gangliosidoses. Hex A is a dimer of two protein subunits, α, 
encoded by HEXA gene and β, encoded by HEXB gene. Hex A is the only isozyme of Hex able to 
cleave GM2 ganglioside in humans.  The GM2 activator protein, encoded by the GM2AP gene is 
also required for GM2 ganglioside cleavage. Mutations in GM2AP result in the AB variant of GM2 
Gangliosidoses. Defects in HexA lead to GM2 accumulation and cellular toxicity. 
 
The three clinical forms of GM2 gangliosidoses are infantile, juvenile, and 
late-onset, classified by their age of onset and disease severity. The most severe 
infantile form is characterized by onset at approximately six months of age and 
premature death within the first five years of life. Infantile forms result from 
mutations that result in little to no HexA activity. Infants develop normally for the 
first 6 months and patients are usually diagnosed at approximately one year of 
age due to regression of, or failure to reach, developmental milestones. 
Symptoms include seizures, deficits in motor function, and dysphagia. Patients 
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eventually decline to a vegetative state before succumbing to the disease. 
Presently the care for these patients consists of palliative measures because 
there is no effective treatment.17 Juvenile and late-onset forms present 
heterogeneously with progressive manifestations of symptoms such as 
psychosis, dystonia, and ataxia.12 
 
Animal models of GM2 gangliosidoses 
SD mice and cats, and TSD sheep are the three available animal models 
of GM2 gangliosidoses whose phenotypes mimic the symptoms seen in human 
patients. A SD mouse model was created which is a knock-out of Hexb gene. SD 
mice accumulate GM2 ganglioside in the brain, show neurological deficits such 
as ataxia, tremors, and loss of motor function, and have a lifespan of only around 
120 days. Interestingly, when this strategy was employed to create a TSD 
mouse, targeting Hexa, GM2 ganglioside storage was milder due to an alternate 
metabolic pathway present in mice where HexB can participate in GM2 
catabolism with sialidase. TSD mice do not have a neurological phenotype.18 
Both the SD cat and TSD Jacob sheep are naturally occurring large animal 
models used to study GM2 gangliosidoses that also accumulate GM2 
ganglioside, both models show a reduction in lifespan, with SD cats living 4.5 ± 
0.5 months and TSD sheep 8-10 months, as well as neurological and motor 
dysfunction14, 19-21. Since their identification almost 40 years ago, SD cats have 
been characterized in great detail.22-28 
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Treatment for Lysosomal Storage Disorders 
A portion of lysosomal enzymes produced by mammalian cells are 
secreted, especially when expressed at supraphysiological levels, and can be 
taken up by the mannose-6-phosphate (M6P) receptor for delivery to the 
lysosomal compartment.29 Termed “cross-correction,” this mechanism is 
exploited by both enzyme replacement therapy (ERT) and gene therapy to 
restore functional enzyme to diseased cells. In the case of gene therapy, only a 
fraction of an organ, tissue, or cell type need to be genetically engineered to 
become an endogenous factory for producing and secreting normal enzyme, 
which is then available to unmodified cells.30, 31 
The current standard of care for LSDs is ERT, in which patients are 
regularly administered recombinant enzyme parenterally.32 ERT is ineffective in 
treating the neurological components of LSDs because of the blood–brain barrier 
(BBB). The structure and physiology of the BBB prevents most high-molecular-
weight substances, including proteins, from entering the CNS. Cell surface 
receptors exist on brain endothelial cells to mediate transport of macromolecules 
into the brain and thus play a fundamental role in homeostasis of the CNS 
microenvironment. Unfortunately, no such mechanism exists to transport 
circulating recombinant lysosomal enzymes across the BBB even when high 
levels are present in the circulation.33, 34 In order to circumvent the BBB, many 
have successfully treated both small and large LSD animal models by injecting 
recombinant lysosomal enzymes directly into cerebrospinal fluid (CSF) via 
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intracisternal, intrathecal, or intracerebroventricular (ICV) administration and this 
approach is also being tested clinically.35-43 
 Another approach that is currently the subject of intense interest is to 
target lysosomal enzymes to the brain via fusion/conjugation with protein 
domains/peptides derived from proteins that are naturally transported across the 
BBB.44-50 
Allogenic stem cell transplantation has been used to treat a variety of 
LSDs, using both hematopoietic stem cells (HSCs) and neural stem cells (NSCs). 
These strategies have been widely improved upon by the use of gene therapy 
and viral vectors, such as lentivirus, to overexpress lysosomal enzymes in these 
cells and by using autologous cell transplantation.51 NSCs derived from patient 
iPS cells have been engineered to overexpress arylsulfatase A (ARSA) and treat 
the metachromatic leukodystrophy (MLD) mouse model.52 Additionally, lentiviral-
mediated ex vivo gene transfer of arylsulfatase A into a patient’s own 
hematopoietic stem cells followed by intravenous reinfusion has been shown to 
attenuate CNS disease progression in an ongoing clinical trial (NCT01560182) 
for MLD.53, 54 
Direct injection of lentiviral vectors encoding for appropriate lysosomal 
enzymes into the brain for MPS VII and MLD have shown improvement in 
disease pathology.55, 56 Similarly, feline immunodeficiency virus-based vectors 
(FIVs) encoding β-glucuronidase were injected into the striatum of MPS VII mice 
and resulted in cognitive improvement.57 
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Adeno-associated viral vector 
Adeno-associated virus (AAV) is a replication-deficient parvovirus. The 
single-stranded 4.7 kb DNA genome is composed of the rep and cap genes 
flanked by inverted terminal repeats (ITR). The AAV virion is a non-enveloped 20 
nm capsid composed of three viral proteins (VP) VP1, VP2, and VP3 at a 1:1:18 
ratio (60 capsomeres total).58 Wild type AAV is prevalent in humans, and had not 
been linked to any disease until a recent publication reported wild type AAV2 
sequences inserted into oncogenes of 6% of examined hepatocellular 
carcinomas (HCC.)59 However, recombinant AAV vectors (rAAV) have very 
different properties than wild type AAV and to date over 100 clinical trials using 
rAAV have never reported HCC development. Still, the long-term safety of most 
rAAV therapies remains to be examined.60, 61 Recombinant AAV vectors are 
devoid of viral coding sequences and carry an ITR-flanked transcription cassette 
consisting of a promoter driving expression of a gene of interest and a 
polyadenylation signal (Figure 1.2). The ITR elements are necessary for vector 
genome replication and packaging during production and postinfection 
processing to generate stable, transcriptionally active genomes in target cells. 
 
 
Figure 1.2 Genomic organization of recombinant adeno-associated viral vectors. 
Recombinant adeno-associated viral vectors contain two inverted terminal repeats, which are 
non-coding and the only viral elements contained in the vector. 
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Recombinant AAV has become the platform of choice for in vivo gene 
delivery to CNS for a number of reasons including its ability to transduce dividing 
and non-dividing cells at high efficiency, mediate long-term gene expression, and 
maintain an excellent safety profile both in animal models and human clinical 
trials. However, the immunology of rAAV-encoded transgenes after gene transfer 
to CNS is an evolving field, and it appears that new more powerful capsids, such 
as AAV9, are also more likely to trigger immune responses than less robust AAV 
serotypes, such as AAV2, when encoding either non mammalian transgenes, 
such as green fluorescent protein (GFP) or species mismatched therapeutic 
genes.62 Most experiments in mouse models of LSDs have been conducted with 
rAAV vectors encoding human enzymes. In some animal models, the therapeutic 
efficacy appears to be compromised by the immune system,63, 64 and it is unclear 
whether this is due to an immune response to a species mismatched enzyme or 
because of the knockout nature of most mouse models in which no protein is 
detectable. This aspect should be considered carefully in the planning of 
preclinical efficacy and safety experiments in large animal models as the use of 
rAAV vectors encoding human enzymes can confound the interpretation of 
outcomes.14 Although the degree of homology between human and other 
mammalian enzymes (especially monkey) is very high, there may be sufficient 
amino acid differences to generate new epitopes that may trigger an immune 
response. The approach that is often employed to test rAAV vectors encoding 
human enzymes in large animals is to use immunosuppression.65-67 For obvious 
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reasons, this can blunt or mask responses that would otherwise become 
apparent and possibly limiting to the implementation of a particular vector design 
and/or delivery route. Finally, the amino acid differences between enzymes from 
different species could alter protein–protein interactions in subtle ways and 
influence both therapeutic outcomes and toxicological profiles. For these 
reasons, we use rAAV vectors encoding species-specific enzymes in our 
preclinical efficacy and safety studies. 
The most commonly used promoters to drive gene expression in rAAV 
vectors are ubiquitous strong promoters such as CBA (also known by the 
designations of CAG or CB), in which the chicken beta-actin promoter is fused to 
the human cytomegalovirus (CMV) immediate early gene enhancer with a 
chimeric intron68. 
For applications in CNS where neuronal restricted expression is desired, 
the human synapsin-1 promoter appears to be quite effective.69 Despite its large 
size (1.7–1.8 kb), the promoter for glial fibrillary acidic protein (GFAP) can be 
used to restrict expression to astrocytes. Additionally, a smaller version, 
gfaABC1D, which is only 681 base pairs has been developed.70 Eighteen 
MiniPromoters compatible with AAV have been developed with targeted CNS 
delivery.71 Furthermore, The ITR elements of AAV have been shown to act as 
promoters in the brain.72, 73 Other transcriptional elements, such as woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) or chimeric introns, 
can be added to increase transgene expression.74, 75 Though the majority of AAV 
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capsids display a high degree of neurotropism in rodent brain, a few serotypes 
such as AAV5 transduce astrocytes and neurons equally well.76-78 The vast 
majority of rAAV vectors carry ITR elements from AAV2, but nonetheless they 
can be packaged at high efficiency in a variety of AAV capsids.79 Many types of 
AAV have been identified that efficiently transduce the CNS such as AAV2, 
AAV1, AAV5, AAV8, AAV9, AAVrh8, and AAVrh10.76, 80-88 Additionally, many 
naturally occurring AAV capsids, such as AAV9 and AAVrh10, as well as novel 
engineered capsids transduce cells in the CNS after intravenous delivery in adult 
mice.89-92 However, the choice of promoter to drive transgene expression 
influences our perception of tropism, as the two are intimately associated. 
AAV mediated gene therapy has been applied to treat many other 
neurodegenerative diseases other than LSDs, including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and 
spinal muscular atrophy (SMA). Therapy for some of these use gene therapy to 
silence gene expression in dominantly inherited diseases by RNA interference.93 
Therapeutic responses have been reported in many of these animal models and 
clinical trials have been started or will be started very soon (TABLE 1.1).93 
Unfortunately, production of humoral immunity and the cross reactivity of 
antibodies towards AAV capsids currently prevents successful readministration of 
these therapies, if necessary. However, much work is being done in modulating 
immune responses and identifying novel capsids that would thwart pre-existing or 
acquired immunity towards AAV.94 
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Table 1.1 Clinical trials for AAV gene therapy for CNS diseases. Modified from Hocquemiller, 
2016.93  
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AAV-mediated gene therapy for Lysosomal storage disorders 
 
LSDs are good candidates for AAV mediated gene therapy since most of 
them are caused by mutations in a single gene and it would provide a permanent 
one-time treatment.  It is also known that correction or improvement of disease 
burden can be seen with only 10-15% normal enzyme activity.95 As stated earlier, 
similarly to ERT, cross-correction would allow a relatively small number of 
endogenous cells genetically modified to overexpress a lysosomal enzyme to 
supply it to a much larger population of cells that could be in a single organ or the 
entire body.93 Distribution of lysosomal enzymes from vector-transduced cells in 
the brain occurs by simple diffusion, as well as retrograde and anterograde 
axonal transport to distant, interconnected structures.96-101 In addition, CSF flow 
in the perivascular space of Virchow-Robin also appears to contribute to the 
widespread distribution of lysosomal enzymes in the brain.102 By utilizing the 
innate properties of lysosomal enzymes and the brain itself, global therapy 
throughout the CNS may be achieved from focal gene delivery. Finally, since 
axonal transport is known to distribute the AAV vector itself, remote foci of 
enzyme-producing cells may be established from a single injection into strategic 
brain structures.76, 101, 103, 104 AAV vectors that can cross the BBB have also 
opened the possibility for intravenous AAV delivery of vectors encoding 
lysosomal enzymes.83, 87 
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Intraparenchymal delivery 
Gene therapy by direct intracranial injections is an attractive method for 
the treatment of LSDs with CNS involvement because it bypasses the BBB, 
requires smaller vector doses than intravenous or CSF delivery, and is targeted 
to the brain more specifically.93 Previous studies have targeted highly 
interconnected structures in the CNS, such as the striatum,105-107 deep cerebellar 
nuclei (DCN),108 ventral tegmental area (VTA),103 or thalamus,109 relying heavily 
on axonal transport of enzymes and possibly also on interstitial fluid flow.76, 101, 
103, 104, 110 A complete list of preclinical studies in small and large animal models 
for LSDs that target the CNS with intraparenchymal injection of rAAVs is 
summarized in Table 1.2. Ten patients with Late infantile neuronal ceroid 
lipofuscinosis (LINCL) were treated in a phase I clinical trial (NCT00151216) 
using AAV2 with 12 injections into the white matter. Overall the therapy was 
deemed safe and showed a slower rate of decline in patients.111 A phaseI I/II 
clinical trial (NCT01414985) for LINCL is ongoing with a new generation of 
AAVrh10 based vectors that have improved enzyme distribution and better 
immunogenicity profile than AAV2. Intracranial injection into the white matter for 
children with MPS type IIIA using AAVrh10 encoding sulfoglucosamine 
sulfohydrolase and sulfatase-modifying enzyme factor 1  (SGSH and SUMF1) 
has also been tested in a phase I/II clinical trial (NCT01474343) with reported 
safety and disease stability after one year, and in one patient improvement was 
observed.112 Injections into the white matter with AAV5 and AAV10 for MPS type 
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IIIB and MLD respectively are also currently being tested in phase I/II trials 
(ISRCTN19853672, NCT01801709) (Table 1.1). 
Our work has focused on targeting AAVrh8 vectors to the thalamus for the 
widespread distribution of lysosomal enzymes in the mammalian brain. The 
thalamus receives afferent input from many structures throughout the CNS and 
relays the information to the cerebral cortex, from which it also receives 
reciprocal input. Therefore, the thalamus can be viewed as the central node of a 
“built-in” network for the dissemination of lysosomal enzymes throughout the 
CNS via axonal transport. Though AAV gene delivery to the thalamus can supply 
therapeutic levels of a lysosomal enzyme to the cerebrum, it is not sufficient to 
treat the cerebellum and spinal cord.109, 113 Therefore, we explored additional 
targets to supply these structures with therapeutic levels of enzyme by combining 
bilateral thalamic infusion with bilateral injections into DCN or delivery into CSF 
via the cerebral lateral ventricles. 
 
CSF delivery 
 Another strategy to treat the CNS has been to deliver AAV vectors through 
CSF infusion, similarly to infusion of recombinant enzymes.  CSF infusion has 
been tested with many AAV serotypes (1,2,4,5,8,9, rh8, and rh10) and through 
many routes including intraventricular and intrathecal administration, as well as 
into the cisterna magna in small and large animal models for LSDs with 
therapeutic success. Intracisternal delivery is easy to achieve in animal models, 
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however, translating this delivery modality to humans may be challenging. An 
alternative approach is to target ependymal cells in the ventricular system 
allowing secretion of enzyme into CSF for subsequent distribution.102, 114 CSF 
delivery can also lead to benefit to non-CNS organs in the absence of serum 
antibodies against the AAV capsid.115 A complete list of preclinical studies in 
small and large animal models for LSDs that target the CSF with rAAVs is 
summarized in Table 1.2. A phase I/II clinical trial (NCT02725580) for Batten 
(CLN6) disease has begun using AAV9 delivered intrathecally by lumbar 
puncture (Table 1).93 The combination of cisterna magna infusion while the 
patient is held in the Trendelenburg position, i.e. head lower than the feet with an 
inclination of about 30o, has improved single injection CSF delivery for SMA.116 
 
Intravenous (IV) delivery 
 Whole body, or systemic, treatment for LSDs is an attractive prospect 
given that all cells in the body require lysosomal enzymes despite the CNS being 
most susceptible to disease pathology in most LSDs. Once patients no longer 
succumb to these diseases due to CNS manifestations other peripheral clinical 
pathologies will likely be uncovered.  AAV capsids, such as AAV9 and AAVrh10 
have the ability to cross the BBB after IV delivery in adult mice and transduce 
cells in the CNS.83, 87 The efficiency and cell-type transduction pattern in the CNS 
in larger animal models, especially for LSDs, has yet to be completely elucidated.  
Reduced transduction, as compared to rodents, was seen with IV delivery of 
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AAV9 to non-human primates.83, 87 Additionally the accumulation of sialic acid, a 
known inhibitor of AAV9, in the CNS of MPS VIII mice prevented CNS benefit 
when delivered IV.117 Adult animals have been successfully treated with IV AAV 
delivery for LSDs, however, intervention at an earlier age is most beneficial. A 
complete list of preclinical studies with IV delivery of rAAV in mouse models for 
LSDs is summarized in Table 1.2. A phase I/II clinical trial using IV delivery of 
AAV9 for SMA (NCT02122952) and MPS IIIA (NCT02716246) have begun 
(Table 1). IV delivery in humans requires very large doses of vector, up to 
~3x1014 vg/kg.93 
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Table 1.2 Preclinical AAV gene therapy studies for lysosomal storage diseases. * indicates 
wild type animals, AMD, a-mannosidosis , GCL, globoid cell leukodystrophy, INCL, infantile 
neuronal ceroid lipofuscinosis, JNCL, juvenile neuronal ceroid lipofuscinosis, LINCL, late infantile 
neuronal ceroid lipofuscinosis, MLD, metachromatic leukodystrophy, MPS, 
mucopolysaccharidosis, MSD, multiple sulfatase deficiency, NPD, Niemann-Pick disease. 
Modified from Hocquemiller, 2016.93 
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Previous and ongoing treatment strategies for GM2 gangliosidoses 
 
Substrate reduction therapy (SRT) 
 N-butyldeoxynojirimycin (NB-DNJ, Miglustat,	 Zavesca) is a small molecule 
oral drug, originally developed as an anti-viral drug for treating HIV.118, 119 It has 
been shown to cross the BBB and impair glycosphingolipid formation through 
inhibition of glucosylceramide synthase, which is required for glycosphingolipid 
synthesis. Thus NB-DNJ began to be tested as a substrate reduction therapy for 
LSDs. The drug was shown to reduce storage in TSD, SD, as well as in the 
closely related LSD, GM1 gangliosidosis mice. Extension of lifespan (42% 
increase in SD mice) was seen in both SD and GM1 gangliosidosis mice.120-124 
NB-DNJ has been shown to benefit both Gaucher and NPC patients.125-127 
Unfortunately, no measured benefit to late-onset TSD or juvenile GM2 
gangliosidoses patients was seen in clinical studies.128, 129 Slight improvement 
was reported in individual patients.130-132  
Another compound which inhibits glucosylceramide synthase, N-(5-
adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DMP, Genz-529468), 
was administered orally to SD mice beginning at 25 days of age and resulted in 
an increase in lifespan (34%, p<0.0001) with reduction in GM2 ganglioside 
storage in the brain.  Interestingly, treated mice showed an increase in brain 
glycosphingolipids despite improved motor function. Therefore benefits seen in 
the SD phenotype could be due to off-target effects of AMP-DMP.133 Additionally, 
ethylenedioxy PIP2 oxalate (3h), an inhibitor of ceramide glucosyltransferase in 
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the glycosphingolipid synthesis pathway and has recently been shown to reduce 
GM2 ganglioside storage in the liver and brain when delivered postnatally to SD 
mice.134 
 
Stem cell transplantation 
  Intracranial transplantation of mouse neural stem cells (mNSCs) into the 
forebrain and cerebellum of newborn SD mice resulted in a 70% extension in 
lifespan. Results were similar when human derived NSCs were used. 
Combination therapy of mNSC transplantation with SRT compounds, NB-DNJ or 
N-butyldeoxygalactonojirimycin (NB-DGJ) provided a synergistic effect and 
extended lifespan to as much as 215 days. A delay of symptom onset was 
observed and Hex levels were approximately 5-28% of wild type levels in well-
engrafted areas. Animals with higher Hex expression survived longer. 
Glycosphingolipid storage was 40% less in mNSC transplated animals and also 
had reduced neuroinflammation.135  
The dual strategy of mNSC transplantation and NB-DNJ treatment was 
tested in a juvenile setting of SD mice where mNSC transplantation occurred at 
postnatal day 0 with NB-DNJ treatment daily from postnatal day 9-15. Brains 
were analyzed for Hex activity and GM2 ganglioside content.  No synergestic 
effect was noted in this context.134  
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Bone marrow transplantation (BMT) 
 SD mice have been treated with BMT between 10 and 16 days of age and 
it was shown to increase their lifespan from 4.5 months up to 8 months of age (P 
< 0.0001) and delay neurological dysfunction, as measured by behavioral testing. 
Hex activity was mostly detected in the spleen and liver and GM2 ganglioside 
storage was reduced mostly in peripheral organs. Little Hex activity was seen in 
the brain as well as no reduction of glycolipid storage or neuropathology.136 It 
was further shown that BMT could reduce the microglial activation and 
inflammatory response associated with the neurodegeneration in SD mice 
without the reduction of glycolipid storage at 4 months of age.137 Unfortunately, 
no benefit to BMT was seen in human SD and TSD patients. Five GM2 
gangliosidoses patients (2 SD, 3 TSD) underwent hematopoietic stem cell 
transplant (HSCT). Their average age of symptom onset was 3.8 ± 2.6 months 
and HSCT occurred on average at 10.4 ± 5.8 months. No benefits were 
observed. At the conclusion of the study 4/5 patients had died. One died from 
complications of the transplant while the other three succumbed to disease 
related causes. The median lifespan of treated patients was 64 months, not 
significantly more than untreated patients.17 Therefore, it has been concluded 
that this is currently not a valid treatment option. 
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Novel isozymes that mimic HexA 
 Traditionally, both HEXA and HEXB genes are delivered to both SD and 
TSD animal models in order to produce ideal HexA isozyme overexpression.138-
140 This strategy also allows both TSD and SD to be treated by the same drug 
product and is mutation agnostic. Due to rAAV DNA packaging size limitations, 
successfully encoding both α- and β-subunits of HexA, along with promoter 
elements has been challenging.  However, multiple groups have explored a 
strategy where novel hybrid subunits have been created by combining the critical 
stability domains as well as GM2 ganglioside and GM2AP interaction sites of the 
HexA α- and β-subunits into a new hybrid subunit.  These novel subunits can 
dimerize and cleave GM2 gangliosdide.  One of these new isozymes, HexM, can 
be packaged into a self-complementary AAV vector. Self-complementary AAV 
vectors have been shown to be more efficient at gene expression by allowing 
transduction without being limited by second strand synthesis that needs to occur 
prior to single stranded rAAVs becoming transcriptionally active.141 Furthermore, 
HexM encoded by AAV9 vectors has been delivered intravenously and 
intracranially to TSD and SD mice and has been shown to ameliorate disease.142-
144 Another hybrid isozyme, mod2b, has been delivered through ICV enzyme 
replacement and was also able to reduce storage and extend lifespan of SD 
mice.145, 146 These hybrid isozymes may improve current therapeutic strategies, 
but also give hope to a vascular delivery approach to treat GM2 gangliosidoses 
since only one vector would have to infect a cell to create an enzyme that is 
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secreted, capable of cleaving GM2 ganglioside, and also uptaken by other cells 
throught the M6P receptor system. This would theoretically also allow for lower 
rAAV doses to be delivered. This, in combination with AAV capsids capable of 
crossing the BBB and transducing the CNS, is likely to be the next generation for 
gene therapy for GM2 gangliosidoses. However, one has to consider that these 
new isozymes are not naturally occurring proteins and upon delivery to humans 
could elicit an immune response. Although, some patients, due to the nature of 
their mutation, make no enzyme at all so this problem is also relevant when 
delivering normal Hex subunits. 
 
AAV mediated gene therapy for GM2 gangliosidoses 
Although early gene therapies for GM2 gangliosidoses included retroviral 
and adenoviral vectors, the field has primarily shifted to using rAAV vectors.147-149 
SD mice have been treated at one month of age by bilateral intracranial 
injections into the striatum and cerebellum or into the hippocampus and 
cerebellum with a combination of two AAV1 vectors, encoding human Hex α- and 
Hex β-subunits. Treated SD mice live as long as 2 years, or the normal lifespan 
of wild-type mice.15, 106 The timing of treatment is critical, with the best survival 
outcomes (615 days, p < 0.0001) occurring at the 4 week old time point, while 12 
week old treated animals show a slight decrease (126 days, p > 0.05) in median 
survival compared to untreated SD mice (131 days).150 Simultaneous delivery of 
two AAVrh8 vectors encoding feline Hex α- and Hex β-subunits has been 
	 24 
successful in treating feline SD CNS pathology and extending lifespan through 
bilateral injection into the thalamus alone or in combination with injection into the 
DCN.14, 151 This dissertation describes similar efficacy in treating SD mice using 
intracranial delivery of AAVrh8 vectors encoding mouse Hex subunits as shown 
previously for other AAV constructs.15, 106, 150, 152 Furthermore, a single injection of 
AAV vectors into the ICV is as effective as DCN injection in complementing the 
therapeutic effect of bilateral thalamic injections in mice and cats.153 Because 
ICV injection is considered safer than DCN injection, we decided to conduct pre-
clinical safety studies using bilateral thalamic injections in combination with ICV 
delivery of an equimolar formulation of two AAVrh8 vectors encoding Hex α- and 
Hex β-subunits.1 
 
Preclinical studies in non-human primates 
 Many pre-clinical safety studies have been conducted in non-human 
primates (NHPs) due to phylogenetic similarities to humans allowing testing of 
the feasibility to scale up from rodent models to humans. Numerous studies have 
been conducted in NHPs to assess safety of AAV gene therapy for metabolic and 
neurological diseases using systemic, cerebrospinal fluid, and intracranial 
delivery routes.66, 67, 93, 116, 154-158 However, such safety studies differ widely in 
delivery route, AAV vector design/dosing, therapeutic gene, and volume/rate of 
injection. Thus, extrapolation of safety to our paradigm is not advisable as we are 
using a novel capsid (AAVrh8) and target (thalamus), which have never been 
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tested in humans. Our previous studies using direct intracranial injections of 
AAVrh8 vectors encoding species-specific Hex α- or β-subunits at 1:1 ratio in 
mice, cats, and sheep have all indicated safety, widespread enzyme distribution, 
and therapeutic efficacy.14, 153 In this dissertation we optimize the gene therapy 
strategies used in SD cats for pre-clinical safety and feasibility using normal 
monkeys. 
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CHAPTER II - 
LONG-TERM CORRECTION OF SANDHOFF DISEASE BY AAVrh8-
MEDIATED GENE TRANSFER OF MOUSE β-N-ACETYLHEXOSAMINIDASE. 
 
Materials & Methods 
AAVrh8-CBA-mHexα/β-WPRE and AAV8-TBG-mHexβ vector production 
A single stranded rAAV vector plasmid described previously159 was used 
to generate the AAVrh8-CBA-mHexα-WPRE and AAVrh8-CBA-mHexβ-WPRE 
plasmids. AAV8-TBG-mHexβ carries a thyroxin-binding globulin (TBG) promoter 
to drive liver-specific gene expression160 and was produced by transient 
transfection of 293 cells and purified by CsCl gradient ultracentrifugation (UMass 
Medical School, Horae Gene Therapy Center, Worcester, MA). AAVrh8 vectors 
were produced by triple transient transfection of 293T cells followed by 
purification with iodixanol gradient and fast protein liquid chromatography as 
previously described.161 Vectors were concentrated using Acrodisc® Units with 
Mustang® Q Membranes (Pall Corporation), buffer exchanged to phosphate-
buffered saline using 10 kDa Slide-A-LyzerTM Dialysis Cassettes (Thermo Fisher 
Scientific), and filtered using Millex-GV Syringe Filter Unit, 0.22 μm, PVDF, 4 mm 
(EMD Millipore). The titers of the vectors were measured by real-time 
quantitative-PCR with primers and probe to the bovine growth hormone (BGH) 
polyadenylation signal common to all vectors as described.161 
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Animal procedures 
 Sandhoff disease (SV/129 Hexb−/−) mice were originally obtained from Dr. 
Richard Proia (NIH).13 In this study, humane endpoint was defined by weight loss 
of 9-20% maximum body weight or the loss of the ability to right themselves 
within 15 seconds when turned on their back. Thirty-day-old mice were injected 
bilaterally into the thalamus with a 1:1 formulation of AAVrh8-CBA-mHexα-WPRE 
and AAVrh8-CBA-mHexβ-WPRE (1 μL each side at 0.1 μL/min; stereotaxic 
coordinates from bregma in mm: ± 1.5 ML, -2.0 AP, and -3.5 from skull surface) 
in addition to bilaterally into deep cerebellar nuclei (0.3 μL each side at 0.1 
μL/min; stereotaxic coordinates from bregma in mm: ± 1.5 ML , - 6.0 AP, - 3.0 
from skull surface) injection or into the left lateral ventricle (2 uL at 0.2 μL/min; 
stereotaxic coordinates from bregma in mm: -1.0 ML, -0.2 AP, -2.0 from skull 
surface) as previously described.1 The animals in the dose escalation groups 
(Figure 2.2) with 3 x 1011 vg AAV8-TBG-mHexβ via the tail vein using a 27G 
insulin syringe (BD Biosciences). Upon sacrifice, one brain hemisphere and half 
of a spinal cord was embedded in Neg-50TM (Richard-Allan Scientific) freezing 
medium and frozen in a 2-methylbutane/dry ice bath (ThermoFisher Scientific) for 
histology. Cerebrum, cerebellum and brain stem were separated from the other 
brain hemisphere and along with the other half of the spinal cord were frozen on 
dry ice for biochemical analysis. All experiments were reviewed and approved by 
the Institutional Animal Care and Use Committee at Boston College (Chestnut 
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Hill, MA), and performed in compliance with the NIH Guide for Care and Use of 
Laboratory Animals, 8th edition. 
 
Behavioral studies 
Inverted screen testing was performed as described previously.122, 162 
Animals were placed on a square wire mesh screen (30 cm2 with 25 mm2 
openings). The screen was slowly inverted over two seconds until secured at a 
60° angle. Latency to fall (2 minute maximum time) and number of hind leg 
movements that occurred while on screen were recorded. Rotarod performance 
was measured on a non-accelerating rotarod at 20 rpm. Mice were given a 1 
minute training session at 4 rpm.  The longest time spent on the rotarod of two 
trials was recorded (60 second maximum time, 20 minute break between trials). 
Wire hang performance was measured and scored as described previously.122 
 
GM2 ganglioside content 
GM2 ganglioside content in the CNS was measured by liquid 
chromatography-tandem mass spectrometry (LC–MS/ MS) using a modification 
on a method described previously at the University of Massachusetts Medical 
School Proteomics and Mass Spectrometry Facility.162 Briefly, 0.01 or 0.04 mg/μl 
of tissue homogenate was diluted in 0.01 M Phosphate Citrate Buffer with 0.1 % 
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Triton X-100 (VWR) pH 4.4 to 25 or 50 μl respectively. Each sample was spiked 
with 200 ng of d3-labeled GM2 (resuspended in methanol, Matreya, LLC). 
Standard calibration curves were made with GM2-ganglioside (resuspended in 
methanol, Matreya, LLC) over the range of 10–5000 ng in Phosphate Citrate 
Buffer with 0.1 % Triton X-100 and also spiked with 200 ng of d3-GM2 and also 
put through the extraction process. Total lipids were extracted twice by vortexing 
and sonicating samples for 30 seconds with 1 mL isopronal:ethyl acetate:water 
(6:3:1), combining both supernatants after centrifugation. Samples were dried, 
and resuspended in 100 μl of 1 part 0.1% (v/v) formic acid (mobile phase A) to 4 
parts methanol:2-propanol:0.1% formic acid (47.5:47.5:4.9, mobile phase B). For 
each sample, 10 μL was injected in duplicate onto a 2.1 x 50 mm Kinetex 
(Phenomenex) C18 (1.7µ,100Å) column using an Acquity HPLC (Waters 
Corporation) coupled to a Quattro Premier XE (Waters) mass spectrometer 
operating in the negative ion electrospray mode. Gangliosides were eluted at 270 
μL/min using the following gradient: 0-1 min (80% B); 1-5 min (80-100% B); 5-7 
min (100% B); 7.1-12 min (80% B). Multiple reaction monitoring (MRM) 
transitions for GM2 (fatty acids: 18:0, d3-18:0, 20:0) were monitored by following 
corresponding (M-H)- precursor ions to the common sialic acid anion fragment at 
m/z 290 (cone voltage, 90V; collision energy, 70 eV; collision gas pressure, 2.2 
μbar). The area of all the individual GM2 lipid species (18:0, 20:0) were 
combined and normalized to the d3-18:0 GM2 lipid species internal standard. 
Briefly, 11.06% of the area of 18:0 GM2 lipid was subtracted from the area of d3-
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18:0 GM2, to correct for d3-18:0 GM2/18:0 GM2 overlap. The ratio of the sum of 
the area of 18:0 GM2 and 20:0 GM2 to the corrected d3-18:0 GM2 was 
calculated and ng of GM2 lipid was determined from the standard curve. Total 
GM2 ganglioside concentrations were then normalized to total protein content in 
tissue homogenate, measured by QuickStartTM Bradford Protein Assay with serial 
dilutions of bovine serum albumin as standard (Bio-Rad). 
  
Hexosaminidase activity 
Freshly frozen tissue was lysed in 0.1 % Triton-X 100 in 0.01 M 
Phosphate Citrate Buffer pH 4.4 using a Qiagen TissueLyser II (Qiagen Inc., CA, 
USA) with 5 mm stainless steal beads (Qiagen Inc., CA, USA 69989) at 15 Hz for 
20 seconds with three pulses.  Lysates were flash frozen in a bath of dry ice and 
95% ethanol and thawed three times and then spun at 13,000 rpm for 5 minutes.  
Hexosaminidase isozyme activities was measured from supernatant using 4-
Methylumbelliferyl N-acetyl-β-D-glucosaminide (MUG, Sigma) and 4-
Methylumbelliferyl 6-Sulfo-2-acetamido-2-deoxy-β-D-glucopyranoside Potassium 
Salt (MUGS, Toronto Research Chemicals) and normalized to total protein 
content measured by QuickStartTM Bradford Protein Assay with serial dilutions of 
bovine serum albumin as standard (Bio-Rad, CA, USA #5000201) as previously 
described.14 Enzyme activity is represented as nmol 4MU/hr/mg protein. 
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Results 
Intracranial delivery of AAVrh8-mHexα/β vector extends lifespan and improves 
motor performance of Sandhoff disease mice. 
 
A 1:1 formulation of AAVrh8 vectors encoding mouse Hexosaminidase 
(Hex) α- and β-subunits was injected intracranially in 4-week old Sandhoff 
disease (SD) mice via two approaches, either a combination of bilateral thalamic 
(TH) and deep cerebellar nuclei (DCN) injections (TH/DCN), or bilateral thalamic 
injections combined with a single lateral intracerebroventricular injection 
(TH/ICV). The behavioral performance of AAVrh8 treated SD mice (4.68 x 109 
vg), and controls (untreated SD and wild type littermates) was assessed over 
time starting at 60 days of age (one month post-injection) (Figure 2.1). The 
inverted screen performance of TH/ICV AAVrh8 treated SD mice was 
significantly better than untreated SD mice at 120 days of age (P ≤ 0.05), and 
both TH/ICV and TH/DCN AAVrh8 treated mice performed comparable to that of 
wild type controls at 180 days (Figure 2.1A). In the rotarod test, both cohorts of 
AAVrh8 treated SD mice performed better than untreated SD controls (P ≤ 0.01) 
at 120 days of age, and their performance was comparable to wild type controls 
to at least 180 days of age (Figure 2.1B). No significant improvement was 
measured in the wire hang test (Figure 2.1C) compared to untreated SD mice. 
Both intracranial delivery approaches resulted in similar extensions of 
lifespan compared to untreated SD mice (P ≤ 0.001 TH/DCN, P ≤ 0.0001 
TH/ICV) and were not significantly different from each other (P > 0.05). Untreated 
SD mice had a median survival of 127 days while SD mice treated via TH/DCN 
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or TH/ICV, at a dose of 4.68 x 109 vg, had a median survival of 424 days and 423 
days, respectively (Figure 2.1D) 
 
 
Figure 2.1 Intracranial AAVrh8-mHexα/β treatment increases lifespan of Sandhoff disease 
mice and results in retained motor performance. The performance of SD mice treated with 
4.68x109 vg of AAVrh8-mHexα/β vector formulation via TH/ICV or TH/DCN delivery in (A) 
inverted screen, (B) rotarod, and (C) wire hang tests was evaluated at 60, 120 and 180 days of 
age. At 60 days wild type n=8, untreated SD mice n=8, TH/ICV treated n=7, TH/DCN treated n=7. 
At 120 days wild type n=8, untreated SD mice n=6, TH/ICV treated n=7, TH/DCN treated n=7. At 
180 days wild type n=7, untreated SD mice n=0 (#: median survival of untreated SD mice was 
127 days and therefore no mice remained at the 180 day timepoint), TH/ICV treated SD n=7, 
TH/DCN treated SD n=6. Results are shown as mean ± SD, Tukey's multiple comparisons test.   
* (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001). (D) Kaplan-Meier survival plot of Sandhoff disease (SD) 
mice treated with 4.68x109 vg AAVrh8-mHexα/β intracranially showing that in combination with 
bilateral thalamic injections (TH), bilateral deep cerebellar nuclei (DCN) injections or a single 
intracerebral ventricular (ICV) injection results in comparable survival outcomes. Dose: 4.68 x 109 
vg. Median survivals: untreated SD mice 127 days (n=8), TH/DCN 424 days (n=8), TH/ICV 423 
days (n=7) Log-rank test between untreated SD mice and TH/DCN or TH/ICV. ** (P ≤ 0.01), **** 
(P ≤ 0.0001). 
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Dose-dependent extension in lifespan with prolonged motor performance in 
Sandhoff Disease mice with AAVrh8-mHexα/β treatment. 
 
It has been shown that intravenous delivery of AAV8 encoding human acid 
sphingomyelinase (hASM), driven by a liver specific promoter, prior to intracranial 
delivery of AAV2-hASM in Niemann-Pick disease mice prevented hASM antibody 
generation and enhanced efficacy of brain injections.64 We tested this systemic-
mediated tolerization approach on SD (HexB-/-) mice.  Two days prior to 
intracranial TH/ICV infusion of AAVrh8-mHexα/β, SD mice were infused 
intravenously with AAV8-TBG-mHexβ (3 x 1011 vg). Systemic injection of AAV8-
TBG-mHexβ alone did not enhance survival of SD mice, as the median survival 
for untreated SD mice was 127 days while for SD mice treated with AAV8-TBG-
mHexβ it was 128.5 days (Figures 2.1D and 2.2A). Furthermore, systemic-
mediated tolerization combined with intracranial therapy did not significantly 
enhance median survival in SD mice compared to intracranial alone at 4.68 x 108 
vg (median survival of combination therapy 448.5 days, TH/ICV alone 423 days) 
(Figures 1.1D and 1.2A). A dose escalation experiment (4.68 x 107, 4.68 x 108 
vg, 4.68 x 109 vg, 1.17 x 1010 vg,) was performed on these mice as well. SD mice 
were pre-treated intravenously with AAV8-TBG-mHexβ before TH/ICV delivery of 
AAVrh8-mHexα/β vectors. Extension in survival was documented only for the two 
highest doses (4.68 x 109 vg and 1.17 x 1010 vg, P ≤ 0.0001). Median survival of 
systemic-only treated SD mice was 128.5 days, 4.68 x 107 vg: 110.5 days, 4.68 x 
108 vg: 135 days, 4.68 x 109 vg: 448.5 days, 1.17 x 1010 vg: 591 days (Figure 
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2.2A). Despite living a maximum of 666 days (1.17 x 1010 vg dose), treated 
animals did eventually present with hind limb weakness and ataxia at time of 
euthanasia and some lost body weight and/or the ability to right themselves when 
placed on their back.  
No significant differences in behavior performance was seen in these 
combination therapy mice treated with 4.68 x 109 vg or 1.17 x 1010 vg intracranial 
TH/ICV doses compared to intracranially untreated SD mice at 120 days when 
measured by inverted screen performance (Figure 2.2B), rotarod performance 
(Figure 2.2C), or wire hang test (Figure 2.2D).  At 180 days of age TH/ICV mice 
dose performed comparable to wild type mice in inverted screen performance at 
both doses (Figure 2.2B). Also at 180 days of age, TH/ICV mice at both doses 
performed comparable to wild type mice in rotarod performance Figure 2.2C). No 
significant improvement was measured in the wire hang test (Figure 2.2D) 
compared to intracranially untreated SD mice around the median survival age of 
untreated SD mice (120 days). However mice were still able to perform the test 
at 180 days when no untreated SD mice were surviving. 
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Figure 2.2 Intracranial AAVrh8-mHexα/β treatment in Sandhoff disease mice provides a 
dose-dependent extension in lifespan and prolongs motor performance. (A) Kaplan-Meier 
survival plot of a dose escalation experiment for AAVrh8-mHexα/β injected intracranially into the 
TH/ICV of 1 month SD mice showing a dose dependent increase in survival of Sandhoff mice 
treated with AAVrh8-mHexα/β bilaterally in the thalamus and intracerebral ventricle at 4.68 x 109 
vg and 1.17 x 1010 vg. Median survivals: intracranially untreated SD mice - 128.5 days (n=8), 1.17 
x 1010 vg - 591 days (n=7), 4.68 x 109 vg - 448.5 days (n=8), 4.68 x 108 vg - 135 days (n=7), 4.68 
x 107 vg -110.5 days (n=8). Log-rank test between untreated and injected groups. ** (P ≤ 0.01), 
**** (P ≤ 0.001). The performance of SD mice treated intracranially with 4.68x109 vg and 1.17 x 
1010 vg of AAVrh8-mHexα/β vector formulation via TH/ICV delivery in (B) inverted screen, (C) 
rotarod, and (D) wire hang tests was evaluated at 60, 120 and 180 days of age. At 60 days wild 
type n=8, intracranially untreated SD mice n=8, TH/ICV treated 4.68x109 vg n=8, TH/ICV 1.17 x 
1010 vg treated n=8. At 120 days wild type n=8, intracranially untreated SD mice n=6, TH/ICV 
4.68x109 vg treated n=8, TH/ICV treated 1.17 x 1010 vg n=8. At 180 days wild type n=7, untreated 
SD mice n=0 (#: median survival of untreated SD mice was 128.5 days and therefore no mice 
remained at the 180 day time point), TH/ICV 1.17 x 1010 vg treated SD n=7, TH/ICV 4.68x109 vg 
treated SD n=8. Results are shown as mean ± SD, Tukey's multiple comparisons test. * (P ≤ 
0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), ***** (P ≤ 0.0001). Note: SD mice were also pretreated with 
intravenous AAV8-TBG-mHexβ (3 x 1011 vg) two days prior to intracranial AAVrh8-mHexα/β 
treatment. 
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Behavioral evaluation of AAVrh8 treated normal mice. 
To assess the potential impact of intracranial AAVrh8 vector infusion in the 
absence of an underlying neurodegenerative process, age matched heterozygote 
(HZ) littermates (HexB+/-) mice received intracranial injection of 4.68 x 109 vg 
AAVrh8 vector formulation via the same routes of administration. AAVrh8 treated 
HZ mice and untreated controls (wild type and HZ) were assessed in different 
behavioral tests over time (Figure 2.3). We did not observed gross alterations in 
the behavior of AAVrh8 injected HZ mice compared to controls, or any impact on 
survival. No differences among cohorts were apparent in the inverted screen test 
(Figure 2.3A). TH/DCN injected HZ mice performed slightly worse than untreated 
HZ and WT controls at 180 days in the rotarod test (Figure 2.3B). There were no 
significant differences in wire hang performance (Figure 2.3C) among cohorts at 
both 60 and 120 days of age.  However, at 180 days TH/DCN injected HZ mice 
performed worse than untreated HZ animals (P ≤ 0.05) and untreated WT 
animals (P ≤ 0.01). There was no significant difference in performance of TH/ICV 
injected animals compared to untreated HZ or WT animals at 180 days of age. 
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Figure 2.3 Intracranial delivery of AAVrh8-mHexα/β has minimal impact on motor 
performance of normal mice. The performance of heterozygous (HexB+/-; HZ) mice treated by 
intracranial injection of 4.68x109 vg AAVrh8-mHexα/β through TH/ICV or TH/DCN delivery was 
assessed at 60, 120 and 180 days of age on the (A) inverted screen, (B) rotarod (B) and (C) wire 
hang tests. At 60 days wild type n=8, untreated HZ mice n=8, HZ TH/ICV treated n=8, HZ 
TH/DCN treated n=8. At 120 days wild type n=8, untreated HZ mice n=8, HZ TH/ICV treated n=8, 
HZ TH/DCN treated n=8. At 180 days wild type n=7, untreated HZ mice n=8, HZ TH/ICV treated 
n=7, HZ TH/DCN treated n=8. Results are shown as mean ± SD, Tukey's multiple comparisons 
test. * (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), **** (P ≤ 0.0001). 
 
 
Widespread CNS expression of Hexosaminidase and reduction of GM2 
ganglioside storage in AAVrh8 treated SD mice. 
 
 GM2 ganglioside content and Hexosaminidase expression in the CNS 
were measured in TH/ICV AAVrh8 treated (1.17 x 1010 vg) SD mice, in untreated 
SD mice, and in untreated WT controls (Figure 2.4). We could not detect GM2 
ganglioside, measured by LC–MS/MS, in the cerebrum of AAVrh8 treated 
	 38 
animals and significant reduction of GM2 ganglioside was seen in the cerebellum 
(91.1%), brainstem (99.6%), and spinal cord (99.8%) (P ≤ 0.0001, Figure 2.4A).  
Total Hexosamindiase activity was restored to the central nervous system 
of AAVrh8 treated SD mice. Levels of activity were above that of wild type in the 
cerebrum and comparable in the cerebellum, brainstem, and spinal cord. 
 
 
 
Figure 2.4 Intracranial AAVrh8-mHexα/β treatment reduces GM2 ganglioside storage and 
results in widespread Hexosaminidase expression in the central nervous system of 
Sandhoff disease mice. Sandoff mice were treated by TH/ICV injection of 1.17x1010 vg AAVrh8-
mHexα/β and at their humane endpoint the cerebrum, cerebellum, and spinal cord were analyzed 
for (A) GM2 ganglioside content and (B) Hexosamindase activity using two artificial substrates, 
MUG (cleaved by HexA, HexB, and HexS isozymes) and MUGS substrate (cleaved by HexA and 
HexS isozymes). Results are shown as mean ± SD, Tukey's multiple comparisons test. **** (P ≤ 
0.0001), n.d. (not detected). N=6 for all cohorts (3 males and 3 females). 
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CHAPTER III - 
DIRECT INTRACRANIAL INJECTION OF AAVrh8 ENCODING MONKEY β-N-
ACETYLHEXOSAMINIDASE CAUSES NEUROTOXICITY IN PRIMATE BRAIN. 
 
Materials & Methods 
Electron Microscopy of AAVrh8 vector preparations 
AAVrh8 vector preparations were analyzed by The Core Electron 
Microscopy Facility at the University of Massachusetts Medical School 
(Worcester, MA) using negative staining. 
 
Silver stain of AAVrh8 vector & Densitometry 
AAVrh8 vector purity was assessed by gel electrophoresis using 4-20% 
Mini-PROTEAN® TGX™ (Bio-Rad) precast gels followed by silver staining 
(Invitrogen) and densitometry. 
 
Endotoxin detection 
Endotoxin levels were measured on AAV vector preparations using the 
Endpoint Chromogenic LAL Assays (The QCL-1000™) from Lonza according to 
manufacturer’s instructions. 
 
AAVrh8-CBA-Hexα/β-WPRE mut6rATG vector production 
 A single stranded rAAV vector plasmid described previously159 was used 
to generate the AAVrh8-CBA-cmHexα-WPREmut6ΔATG and AAVrh8-CBA-cmHexβ-
WPREmut6ΔATG plasmids. The woodchuck hepatitis virus post-transcriptional 
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regulatory element was modified to include the previously described mut6 
mutations in the putative promoter region of protein X163 as well as replace all 
putative ATG codons with TTG. This modified WPREmut6rATG was synthesized by 
overlapping polymerase chain reaction (PCR).  
Modified WPRE sequence: 
GATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAA
CTTTGTTGCTCCTTTTACGCTTTGTGGATACGCTGCTTTATTGCCTTTGTATC
TTGCTATTGCTTCCCGTTTGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGG
TTGCTGTCTCTTTTTGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTG
GTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACC
ACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGG
CGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTG
TTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTT
GGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCT
ACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGC
CGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGG
ATCTCCCTTTGGGCCGCCTCCCCGCATCGGACTAG. 
 AAVrh8 vectors were produced by triple transient transfection of 293T 
cells followed by purification using iodixanol gradient and fast protein liquid 
chromatography as previously described.161 Vectors were then concentrated 
using Acrodisc® Units with Mustang® Q Membranes (Pall Corporation), buffer 
exchanged to phosphate-buffered saline using 10 kDa Slide-A-Lyzer™ Dialysis 
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Cassettes (Thermo Fisher Scientific), and filtered using Millex-GV Syringe Filter 
Unit, 0.22 µm, PVDF, 4 mm (EMD Millipore). The titers of the vectors were 
measured by real-time quantitative-PCR with primers and probe to the bovine 
growth hormone (BGH) polyadenylation signal as described.161 
 
Non-human primates 
 Male and female cynomolgus macaques (1.5-2.5 year-old) were 
purchased from Worldwide Primates Inc. (Miami, FL) and selected for this study 
based on the absence of AAVrh8 neutralizing antibodies in serum (<1:10), 
measured as previously described.164 All experiments were reviewed and 
approved by the Institutional Animal Care and Use Committee at the University of 
Massachusetts Medical School (Worcester, MA), and performed in compliance 
with the NIH Guide for Care and Use of Laboratory Animals, 8th edition. 
 
Intracerebral injection of AAVrh8 vectors or PBS and imaging in animals 
Three doses (3.2 x1012 vg (1x cohort: n=3), 3.2 x1011 vg (1/10th cohort: 
n=2), or 1.1x1011 vg (1/30th cohort, n=2)) containing a 1:1 ratio of AAVrh8 
vectors encoding cmHexα- and cmHexβ-subunits along with control groups 
injected with vehicle (phosphate buffered saline (PBS), n=1) or 3.2 x1012 vg of an 
AAVrh8 vector without a transgene (TGE, n=2) were tested. Neurosurgical 
procedure, injection, and imaging were performed as previously described.1, 165, 
166 Targeting and trajectory planning occurred through fusion of live operative 
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fluoroscopy and cone-beam computed tomography scans with pre-surgical 
magnetic resonance imaging (MRI). Bilateral injections into the thalamus 
occurred simultaneously (150 µl per side) with an infusion rate of 2 µl/min using a 
16G SmartFlow™ neuroventricular cannula (MRI Interventions, Inc). 
Approximately 10 minutes after infusion the cannulas were withdrawn from the 
brain and followed by injection into the left cerebral lateral ventricle (300 µl) at a 
rate of 50 µl/min using a 16G SmartFlow™ neuroventricular cannula (MRI 
Interventions, Inc). In all cohorts each thalamus received 1/4th of the total AAV 
vector dose and the left cerebral lateral ventricle received half. Injection volumes 
were kept constant across cohorts. 
 
Clinical Monitoring and Neurological Assessment 
 Monkeys were assessed in their home cage before surgery and weekly as 
described.167 Behavior of monkeys in their home cage was also evaluated using 
a camcorder to document behavior before surgery and at 7, 15, 30, 60, and 90 
days post-surgery. Spontaneous behavior (recording the monkey for 3.5 minutes 
while absent from the room), food presentation and response (to handing animal 
treats or placing treats in the food hopper for 1 minute), as well as response to 
threat (approaching animal’s cage while looking directly at the monkey for 1 
minute) were all documented. 
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Measurement of antibody titers in serum 
 Serum antibody titers towards AAVrh8 vector or purified human Hex α-
subunit (Sigma) were measured using an ELISA assay as previously described.14 
Titers <1:8 were considered not detectable. 
 
Tissue collection, processing, histopathology, histochemistry, and 
immunohistochemistry 
 
Fresh, unperfused tissue was collected from animals in the highest dose 
cohort (3.2x1012 vg) as well as from the PBS control group. Animals from 3.2 
x1011 vg dose cohort, 1.1x1011 vg dose cohort, and control animals receiving 
AAVrh8 vector without a transgene were perfused with cold phosphate buffered 
saline prior to tissue collection. Following death, a complete necropsy was 
performed. All tissues collected were fixed in 10% neutral buffered formalin 
(NBF) and paraffin embedded according to standard procedures. Five µm 
histologic sections were routinely processed and stained with hematoxylin and 
eosin (HE). Luxol fast blue histochemical staining was performed based on 
standard procedures. To characterize the immune cell infiltrate of the lesions, 
immunohistochemistry for CD3, CD20, and CD68 were performed. Briefly, all 
staining protocols used an antigen retrieval protocol of microwaving slide-
mounted sections in 0.1M sodium citrate buffer for 20 minutes followed by 20 
minutes of cooling at room temperature (RT). CD3 (Dako, Carpinteria, CA; 
catalog #A0452) was applied for 30 minutes at room temperature at a dilution of 
1:600. CD20 (Dako, Carpinteria, CA; catalog #M0755) and CD68 (Dako, 
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Carpinteria, CA; catalog #M0814) were applied overnight at 4°C at a dilution of 
1:179 and 1:410 respectively. Secondary antibodies were biotinylated horse anti-
mouse (Vector Laboratories, Burlingame, CA) or biotinylated goat anti-rabbit 
(Vector Laboratories) as appropriate, diluted 1:200, and incubated for 30 minutes 
at room temperature. Tertiary reagent in each case was Vectastain ABC Elite 
reagent (CD3) or Vectastain ABC Standard reagent (CD20, CD68) incubated for 
30 minutes at RT (Vector Laboratories). All slides were developed with DAB 
chromogen (Dako) and counterstained with Mayer’s hematoxylin. Negative 
controls consisted of adjacent brain sections stained with irrelevant species-, 
isotype-, and concentration-matched antibodies. Lymph node served as a 
positive control tissue for all antibodies.  
 
Western blotting 
Tissues were lysed from 3 mm biopsy punches of the thalamus in T-
PER™ Tissue Protein Extraction Reagent (Thermo Scientific) containing 
cOmplete Protease Inhibitor Cocktail (Roche). Total protein was measured using 
QuickStartTM Bradford Protein Assay with serial dilutions of bovine serum 
albumin as protein standard (Bio-Rad). Total protein lysates (20 μg) were 
resolved using SDS-polyacrylamide gel electrophoresis with 4-20% Mini-
PROTEAN® TGX™ (Bio-Rad) precast gel in 25 mM Tris 190 mM Glycine 0.1% 
sodium dodecyl sulfate followed by wet transfer to a 0.22 μm nitrocellulose 
membrane (Maine Manufacturing, LLC) in 25 mM Tris 190 mM Glycine. 
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Membranes were blocked for 1 hour in 5% non-fat dry milk in Tris-Buffered 
Saline with 0.05% Tween™ 20 (TBST) and probed with rabbit anti-Hex α-subunit 
antibody (LifeSpan BioSciences, Inc.) or mouse anti- Hex β-subunit antibody14 
diluted 1:1,000 in 5% non-fat dry milk in TBST and incubated overnight at 4°C. 
HRP-conjugated secondary antibodies (anti-mouse or anti-rabbit, GE Healthcare) 
were diluted 1:5,000 in 5% non-fat dry milk TBST and incubated for 1 hour at 
room temperature. Signal was detected using Pierce ECL Western Blotting 
Substrate (ThermoFisher Scientific) followed by exposure to Amersham 
Hyperfilm ECL (GE Healthcare). Membranes were stripped using 100 mM 
glycine (pH 4.0) for 25 minutes, washed in TBST and then blocked and probed 
again using HRP-conjugated mouse anti-β-actin antibody (GenScript) diluted 
1:1,000 in 5% non-fat dry milk in TBST for 1 hour and detected as before. 
 
Hexosaminidase activity 
Hexosaminidase isozyme activities were measured from fresh frozen 
tissue either from 3 mm biopsy punches from the thalamus of 4 mm coronal 
blocks or from 2 mm slices from thoracic spinal cord coronal blocks. Enzyme 
activity was measured using 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide 
(MUG, Sigma) and 4-Methylumbelliferyl 6-Sulfo-2-acetamido-2-deoxy-β-D-
glucopyranoside Potassium Salt (MUGS, Toronto Research Chemicals) and 
normalized to total protein measured by QuickStartTM Bradford Protein Assay 
with serial dilutions of bovine serum albumin as protein standard (Bio-Rad) as 
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previously described.14 Enzyme activity is represented as nmol 4MU/hr/mg 
protein. 
   
Fluorescent immunostaining 
 Formalin-fixed paraffin sections (5 µm thick) were used for 
neuropathological evaluation. Paraffin was removed from tissue mounted slides 
with two 8 minute incubations in xylenes and then section were rehydrated with 
serial 4 minute incubations in 100%, 95%, and 80% ethanol followed by 1x 
phosphate buffered saline (PBS). For antigen retrieval, slides were boiled in 
10mM Tris 1mM EDTA (pH 9.0) for five minutes and then cooled for 20 minutes. 
Blocking with permeabilization was done for 1 hour in 5% normal goat serum 
(SouthernBiotech) in PBS with 0.05% Tween-20 (Acros). Sections were 
incubated with primary antibodies diluted in 5% normal goat serum in PBS with 
0.05% Tween-20 for 1 hour at room temperature at the following concentrations: 
rabbit anti-HEXA, 1:1000 (LifeSpan BioSciences, Inc.), mouse anti-HEXB, 
1:1000,14 or NeuN, 1:1,000 (EMD Millipore). Sections were washed 3 times in 
TBST and secondary antibodies against the appropriate species and conjugated 
to the different fluorophores (Alexa-488 or Alexa-555, ThermoFisher) were 
diluted 1:1000 in 5% normal goat serum in PBS with 0.05% Tween-20 and 
incubated for 30 minutes followed by 3 washes in PBS. Sections were stained for 
1 minutes in Thermo Scientific™ Pierce™ DAPI (4',6-diamidino-2-phenylindole) 
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 Nuclear Counterstain diluted in PBS. Coverslips were mounted on slides using 
PermaFluor aqueous mounting medium (ThermoFisher). 
 
In situ hybridization 
 RNAscope fluorescent multiplex kit (Advanced Cell Diagnostics) was used 
for in situ analysis of vector derived mRNA in tissue sections using a 
WPREmut6rATG specific probe set (Advanced Cell Diagnostics). Formalin-fixed 4 
µm paraffin brain sections were used according to the manufacturer’s 
instructions. 
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Results 
Experimental Design 
  
The goal of this study was to assess the safety of a formulation of two 
AAVrh8 vectors (1:1 ratio) encoding Hex α- and β-subunits injected bilaterally 
into the thalamus and one cerebral lateral ventricle in cynomolgus macaques 
(cm). Vector purity, endotoxin levels, and empty capsid ratios were measured 
(Figure 3.1). These vectors encoded cm Hex proteins to reduce the likelihood of 
a confounding immune response triggered by delivery of Hex proteins from other 
species. All subjects were selected for the absence of AAVrh8 neutralizing 
antibody titers (<1:10). The study included three dosing cohorts: 3.2 x1012 vg (1x 
cohort: n=3), 3.2 x1011 vg (1/10th cohort: n=2), and 1.1x1011 vg (1/30th cohort, 
n=2) of AAVrh8-cmHex vectors, and control groups injected with vehicle PBS, 
n=1) or 3.2 x1012 vg of an AAVrh8 vector without a transgene (TGE, n=2). The 1x 
dose was based on the efficacious dose in SD cats by vg/kg brain weight.153 
Safety was determined by neurological behavioral assessments, MRI data 
obtained at endpoint (90 days), and pathological examination of tissues. 
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Figure 3.1 Characterization of AAVrh8 vectors. (A) Schematic of the two AAVrh8 vectors used 
in this study. ITR: inverted terminal repeat, CBA: CMV enhancer fused to chicken β-actin 
promoter, CI: chimeric intron, cm: cynomolgus macaque, Hex: Hexosaminidase, WPREmut6rATG: 
modified Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element, pA: bovine growth 
hormone poly-adenylation site. (B) Silver stain on AAVrh8 viral preparations. (C) Electron 
microscopy of AAVrh8 preparations detected by negative stain. Darkly stained structures indicate 
empty viral capsids (arrows). (D) AAVrh8 preparation purity determined by densitometry of silver 
stain in (B) as well as endotoxin levels measured in AAVrh8 preparations. 
 
Clinical Observations 
All monkeys tolerated and recovered well from the surgical procedure. 
However, monkeys in the highest dose cohort (1x) started to show neurological 
symptoms at 2-3 weeks after injection. Symptoms included general weakness of 
limbs, ataxia, inability to perch, and reduced food intake. The neurological 
function of these animals declined rapidly and they became apathetic, which led 
to premature euthanasia between 20-28 days after surgery. In the 1/10th dosing 
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cohort, animals appeared normal until 33 and 48 days after injection when they 
began to develop chorea and dyskinesia during voluntary movement, such as 
when reaching out for food. From this cohort the animal that developed 
symptoms at 33 days required euthanasia at 57 days due to lethargy and non-
responsiveness. However, the other animal in this cohort survived to the 90-day 
study endpoint. In the 1/30th dosing cohort, one animal lost voluntary use of its 
right arm at 59 days and required euthanasia due to lethargy at 66 days. The 
other animal in this cohort did not develop any major clinical signs and survived 
to the 90-day study endpoint (Table 3.1). Despite no outward clinical symptoms 
in this animal, a brain MRI before necropsy indicated alterations in the thalamus 
(Figure 3.2). No clinical signs were observed in the control cohorts, which 
consisted of a PBS injected animal as well as two animals injected with a 
transgene empty (TGE) AAVrh8 vector at the 1x dose (Table 3.1, Figure 3.2). 
 
Table 3.1 Summary of neurological symptoms observed in study animals. For each animal, 
vector dose, day of symptom onset, length of survival, and observed clinical signs are indicated. 
The pre-determined endpoint of the study was 90 days. (TGE: transgene empty, PBS: phosphate 
buffered saline) 
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Figure 3.2 Corresponding coronal sections of brain T2-weighted MRI at pre-
surgery and pre-necropsy indicating signal alterations at endpoint in treated 
animal. Hyperintensities (arrows) detected in the thalami of an animal injected with 
1.1x1011 vg (1/30th dose) of AAVrh8 vector formulation encoding cmHexα or cmHexβ 
subunits. No hyperintensities were noted at any time point in the thalami of an animal 
treated with a transgene empty vector. 
 
Pathology 
 Serum antibody titers to human recombinant HexA and AAVrh8 capsid 
were measured at both pre-injection and necropsy. There were no detectable 
titers (<1:8) to the HexA protein before injection or at necropsy in all animals. At 
necropsy animals receiving vector (including TGE control) had AAVrh8 capsid 
serum antibody titers ranging from 1:128 – 1:49,152. The PBS injected animal 
did not have any AAVrh8 capsid antibody titers (Table 3.2). 
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Table 3.2 Serum titers against recombinant human Hexα-subunit and AAVrh8 capsid. The 
pre-surgery and necropsy titers measured by ELISA against Hexα and AAVrh8 capsid for each 
animal and their dosing cohorts are indicated. ND: not detected. *Pre-surgery AAVrh8 titers were 
measured by neutralizing antibody screen to select animals. 
 
Histological examination of the brain revealed widespread neuropathology 
in the thalamus of animals injected with AAVrh8 encoding Hex. Alterations 
included the presence of granular eosinophilic inclusions in neurons (Figure 
3.3A), necrotic areas with vacuolation (Figure 3.3B), perivascular cuffing (Figure 
3.3C), and white matter loss indicated by lack of luxol fast blue stain (Figure 
3.3D). Neurons with eosinophilic inclusions were also observed in the thalamus 
of the other NHPs injected with lower doses of AAVrh8-cmHex vectors (Figure 
3.3E). There was no evidence of neuropathology in other regions of the brain 
with the exception of that associated with needle tracks. All control cohorts had 
mostly normal histological appearance in the thalamus (Figure 3.3F) with only 
small lesions present near the injection site or needle tracks. 
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Figure 3.3 Neuropathology. (A) H&E staining indicating the presence of granular 
eosinophilic inclusions in neurons of the thalamus of injected animals. Box indicates 
location of magnified region. Magnification 40x. (B) Necrotic area in thalamus with 
vacuolation. Magnification 10x. (C) Example of peri-vascular cuff in thalamus. 
Magnification 20x. (D) In this Luxol fast blue-stained section, arrows delineate one large 
area of necrosis, vascular proliferation, and white matter loss (note pallor compared to 
adjacent dark blue color). Magnification 10x. (E) Similar neuropathology was seen even 
in the lowest dosing cohort. 10x (F) Normal thalamus in PBS injected animal 
Magnification 10x; (1x cohort, A-D; 1/30th cohort, E; PBS injected, F). Tissue sections for 
histological assessment shown in A, B, C, E, and F were stained with hematoxylin and 
eosin. 
 
Analysis of the types of immune cells by immunohistochemistry revealed 
the presence of T-cells (CD3+) and B-cells (CD20+) in perivascular cuffs but little 
to none elsewhere in the thalamus (Figure 3.4A-B). However, there was a large 
macrophage/microglial presence as shown in CD68 immunostaining in the 
thalamus (Figure 3.4C). These findings were common to all subjects treated with 
AAV-cmHex vectors, but not in NHPs treated with either PBS or transgene-empty 
AAV vector. 
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Figure 3.4 Immunological profile of perivascular cuffs in AAVrh8-cmHexα/β 
injected monkey thalamus. (A) CD3 immunostaining for T-cells. (B) CD20 
immunostaining for B-cells. (C) CD68 immunostaining for macrophages/microglia. (A-C; 
1/10th cohort animal) Magnification 20x. 
 
Hexosamindase expression and localization 
 Western blot analysis of Hex α- and Hex β-subunit protein levels revealed 
increased levels in the thalamus of animals injected with AAVrh8 vectors 
encoding cmHexα/β (Figure 3.5A). Accordingly, hexosaminidase activity in the 
thalamus and spinal cord of animals injected with AAVrh8 vectors encoding 
cmHexα/β was considerably higher than in control animals, in some instances by 
>100-fold (Figure 3.5B). This large increase in hexosaminidase expression was 
still present despite the neuronal loss observed in the thalamus (Figure 3.3). 
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Figure 3.5 Increased Hex expression and activity in the CNS. (A) Western blot 
analysis of Hex α- or β-subunit protein levels in thalamus lysates from PBS injected 
control and two animals from 1/10th cohort. (B) Hex activity was measured in the 
thalamus and thoracic spinal cord on all cohorts. MUG substrate is cleaved by HexA, 
HexB, and HexS isozymes. MUGS substrate is preferentially cleaved by HexA and HexS 
isozymes. Note: Due to an emergency euthanasia and necropsy the identity of the 
thalamus (left or right) in animal is 909589 is unknown. 
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Despite massive neuronal loss (Figure 3.3) there were still numerous cells 
in the thalamus expressing both Hex subunits as shown by double 
immunofluorescence staining for Hex α- and Hex β-subunits (Figure 3.6A). Many 
transduced cells were neurons given the co-localization of Hex α-subunit with 
NeuN (Figure 3.6B). In situ hybridization in parallel sections using a WPRE probe 
indicated that cells overexpressing Hex subunits were likely to be AAV vector 
transduced cells (Figure 3.6C). 
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Figure 3.6 Hexα- or Hexβ-subunit localization in monkey thalamus. (A) Immunofluorescence 
staining for Hexα (green) and Hexβ (magenta) subunits and their co-localization (white). Box 
indicates location of magnified region. Magnification 40x. (B) Immunostaining for Hexα-subunit 
(green) and NeuN (magenta). Magnification 40x. (C) RNA in situ hybridization with probe for 
WPRE (red) expressed by AAV transduced cells. DAPI stain (cyan) Magnification 20x. 
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CHAPTER IV - 
OPTIMIZATION OF AAV VECTOR DESIGN FOR SAFE EXPRESSION OF β-N-
ACETYLHEXOSAMINIDASE IN THE BRAIN FOR GM2 GANGLIOSIDOSES 
GENE THERAPY. 
 
 
Materials & Methods 
AAVrh8 vector production 
A single stranded rAAV vector plasmid described previously159 was used 
to generate AAVrh8-CBA-cmHexα/β-WPREmut6ΔATG, AAVrh8-CBA-cmHexα/β, 
AAVrh8-CB-CI-cmHexα/β, AAVrh8-CB-cmHexα/β, AAVrh8-P2-CI-cmHexα/β, 
AAVrh8-P2-cmHexα/β, AAVrh8-cmHexα/β, AAVrh8-CBA-WPREmut6ΔATG, 
AAVrh8-CBA-mHexα/β-WPREmut6ΔATG, and AAVrh8-CB-CI-mHexα/β plasmids. 
The P2 promoter sequence is from US Patent No. US 6,346,415 Bl, (example 1-
7). Sequences of the promoters and other transcriptional elements can be found 
in Appendix A. AAVrh8 vectors were produced by triple transient transfection of 
293T cells followed by purification using iodixanol gradient and fast protein liquid 
chromatography as previously described.161 Vectors were then concentrated 
using an Amicon Ultra-15 Centrifugal Filter Unit (100 kDa), buffer exchanged to 
phosphate-buffered saline using 10 kDa Slide-A-LyzerTM Dialysis Cassettes 
(Thermo Fisher Scientific), and filtered using Millex-GV Syringe Filter Unit, 0.22 
μm, PVDF, 4 mm (EMD Millipore). The titers of the vectors were measured by 
real-time quantitative-PCR with primers and probe to the bovine growth hormone 
(BGH) polyadenylation signal as described.161 
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Animal procedures 
All experiments were reviewed and approved by the Institutional Animal 
Care and Use Committee at University of Massachusetts Medical School 
(Worcester, MA), and performed in compliance with the NIH Guide for Care and 
Use of Laboratory Animals, 8th edition. 
 
AAVrh8 vector screen in nude mice 
 Ten- to twelve week-old male athymic nude mice were obtained from 
Charles River Laboratories and injected with an equal mixture of AAVrh8-
cmHexα/β vectors bilaterally into the thalamus (2 μL each side, 0.1 μL/min, 1.5 
mm medial and lateral, 2.0 mm posterior, 3.5 mm ventral to bregma) and into the 
left lateral ventricle (4 μL, 0.2 μL/min, 1.0 mm lateral, 0.2 mm posterior, 2.0 mm 
ventral to bregma) at a dose of 1.32 x 1010 vg as previously described.1 Control 
groups included mice injected with an AAV vector without transgene (Chapter III), 
phosphate buffered saline (PBS), and non-injected mice (N=8 for all experimental 
and control groups). Mice were killed at 1 month post-injection for biochemical 
(n=4) and histological analysis (n=4). For biochemical analysis of 
Hexosaminidase expression the cerebrum was blocked into four coronal 
sections: C1: olfactory bulbs and first 3 mm, C2: following 2 mm, C3: following 3 
mm, C4: following 2 mm, and the cerebellum, brainstem, and spinal cord were 
separated. Tissue was immediately frozen on dry ice and stored at -80°C. For 
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histology brains were fixed in 10% neutral buffered formalin (NBF) and paraffin 
embedded according to standard procedures at the University of Massachusetts 
Medical School Morphology Core Facility (Worcester, MA). 
 
AAVrh8 vector screen in primates 
Non-human primates 
Male and female cynomolgus macaques (1.5-2.5 year-old) were 
purchased from Worldwide Primates Inc. (Miami, FL) and selected for this study 
based on the absence of AAVrh8 antibodies in serum (<1:10), measured by 
ELISA as previously described.14  
 
Intracerebral injection of AAVrh8 vectors or PBS and imaging in animals 
A 1:1 ratio of AAVrh8 vectors containing encoding cmHexα- and cmHexβ-
subunits at a dose of 3.2 x1011 vg with 2 mM gadolinium (Magnevist®, Bayer) 
were injected into the thalamus and lateral ventricle of cynomolgus macaque 
(n=2 per group) as described earlier (Chapter III). 
 
Clinical Monitoring and Neurological Assessment 
Monkeys were assessed in their home cage before surgery and weekly. 
Behavior of monkeys in their home cage was also evaluated using a camcorder 
to document behavior before surgery and at 7, 15, 30, 60, and 90 days post-
surgery as previously described (Chapter III). 
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Tissue collection 
 Monkeys were perfused with cold phosphate buffered saline prior to tissue 
collection. Brain was blocked into 4 mm coronal slices and every other slice was 
frozen on dry ice and stored at -80°C and the remaining slices and other tissues 
were fixed in 10% neutral buffered formalin (NBF) and paraffin embedded 
according to standard procedures at the New England Primate Research Center 
(Southborough, MA). 
 
AAVrh8-CB-CI-mHexα/β efficacy studies in Sandhoff Disease mice 
A colony of Sandhoff Disease (SV/129 Hexb−/−) mice13 was established at 
the University of Massachusetts Medical School (Worcester, MA) from founders 
kindly provided by Dr. Gerhard Bauer at the University of California, Davis 
(Davis, CA) and Dr. Thomas Seyfried at Boston College (Boston, MA). For short-
term biochemical analysis of GM2 ganglioside content and Hexosaminidase 
activity (Figure 3.11), thirty day old SD mice were injected with 1:1 mix of 
AAVrh8-mHexα/β vectors bilaterally into the thalamus (1 μL each side, 0.1 
μL/min, stereotaxic coordinates from bregma in mm: AP: -2.0; ML: ± 2.0; DV from 
brain surface: -3.5) and into the left lateral ventricle (2 μL, 0.2 μL/min, stereotaxic 
coordinates from bregma in mm: AP: +0.2; ML: 1.0; DV from brain surface: -2.0) 
at doses of 4.68 x 109 vg or 2.34 x 1010 vg as previously described.1 Control 
groups included mice injected with PBS and non-injected mice. Tissue from the 
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CNS was collected 8 weeks post infusion and immediately frozen on dry ice and 
stored at -80°C. 
For survival studies (5 month of age endpoint), Sandhoff disease (SD) 
mice were injected with 2.34 x 1010 vg of an equal mixture of AAVrh8-CB-CI-
mHexα/β into the thalamus (1 μL each side, 0.1 μL/min, same stereotaxic 
coordinates as above) and into the left lateral ventricle (2 μL, 0.2 μL/min, same 
stereotaxic coordinates as above) at 30 days of age (n=8). Control animals 
included untreated Sandhoff Disease mice (n=6). Humane endpoint was defined 
by weight loss of 9-20% maximum body weight or the loss of the ability to right 
themselves within 15 seconds when turned on their back. 
For short-term biochemical analysis of GM2 ganglioside content after dose 
escalation of ICV dose (Figure 3.12), a 1:1 mix of AAVrh8-CB-CI-mHexα/β 
vectors were injected bilaterally into the thalamus (1.17 x 1010 vg, 1 μL each side, 
0.1 μL/min, same stereotaxic coordinates as above) and into the left lateral 
ventricle at four different doses: (1.17 x 1010 vg- 2 μL, 2.34 x 1010 vg- 4 μL, 5.85 x 
1010 vg- 10 μL, 5.00 x 1011 vg- 10 μL at 0.2 μL/min, same stereotaxic coordinates 
as above). Brain, cerebellum and spinal cord were collected 4 weeks post 
infusion and immediately frozen on dry ice and stored at -80°C. 
 
Histology 
Paraffin sections (5 µm) were routinely processed and stained with 
hematoxylin and eosin (H&E), or immunostained with Iba-1 (1:1000, Wako 019-
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19741), and GFAP (1:340, Dako Z0334) at the University of Massachusetts 
Medical School Morphology Core Facility (Worcester, MA). Fluorescent 
immunostaining of Hexosaminidase was performed using rabbit anti-HEXA, 
(1:1000, LifeSpan BioSciences, Inc.) as described previously (Chapter III). 
 
Hexosaminidase activity 
Hexosaminidase isozyme activities were measured from fresh frozen 
tissue. Enzyme activity was measured using the artificial substrates 4-
Methylumbelliferyl N-acetyl-β-D-glucosaminide (MUG, Sigma) and 4-
Methylumbelliferyl 6-Sulfo-2-acetamido-2-deoxy-β-D-glucopyranoside Potassium 
Salt (MUGS, Toronto Research Chemicals) and normalized to total protein 
measured by QuickStartTM Bradford Protein Assay with serial dilutions of bovine 
serum albumin as standard (Bio-Rad) as previously described (Chapter II).14  
Enzyme activity is represented as nmol 4MU/hr/mg protein. 
 
GM2 ganglioside content 
GM2 ganglioside content in the CNS was measured from fresh frozen 
tissue by liquid chromatography-tandem mass spectrometry (LC–MS/ MS) as 
described earlier (Chapter II). 
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Results 
Experimental Design 
The goal of this study was to design a new AAVrh8 vector to express β-N-
acetylhexosaminidase (Hexosamindase, Hex) in the brain at therapeutic levels in 
the absence of the unexpected toxicity documented in monkeys injected with the 
original AAVrh8-CBA-cmHexα/β-WPREmut6ΔATG vector (Chapter III). Six new 
AAVrh8 vector designs encoding cynomolgus macaque Hex α- and β-subunits 
were generated by systematic removal and/or replacement of different elements 
likely to have an effect on the strength of transgene expression to generate a 
series of vectors covering a broad range of enzyme overexpression (Figure 4.1). 
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Figure 4.1 Panel of new AAV vectors with an expected gradient of HexA expression levels. 
Systematic removal of expression elements from the original AAV vector design (top) to its most 
basic form without a classical promoter element of ITR-flanked cDNA with a polyadenylation 
signal (bottom vector) in order to reduce expression levels of Hexosaminidase. ITR: Inverted 
terminal repeat, CMV En: cytomegalovirus enhancer, CB: chicken β-actin promoter, CI: chimeric 
intron, WPRE: woodchuck hepatitis virus posttranscriptional regulatory element, pA: 
polyadenylation signal. 
 
 
Hexosaminidase activity and expression in nude mouse brain 
Hex activity was measured in the CNS of athymic nude mice one month 
after intracranial delivery of 1.32 x 1010 vg AAVrh8-Hexα/β vectors (Figure 4.1) 
using the artificial substrates MUG (Figure 4.2), cleaved by all isozymes of Hex, 
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and MUGS (Figure 4.3), cleaved by HexA and HexS. Relative Hex activity in the 
coronal brain block containing the injection site is shown in Table 4.1 to 
summarize the findings and identify group numbers. The original AAV vector pair 
(Group 1) generated Hex activities ~400-1,700 fold above normal. Other AAV 
vector pairs generated Hex activities in the brain 123-563 fold (Group 2), 20-30 
fold (Group 3), and 13-80 fold (Group 5) above normal providing the anticipated 
range of 1-2 log of activities in AAV-mediated Hex expression in brain. Other 
AAV vectors pairs (Groups 4, 6, and 7) did not generate Hex activity above 
normal levels in athymic nude mouse brain. In control groups (Groups 8, 9) the 
brain Hex activity was comparable to that in naïve mice (Group 10) (Figure 4.1, 
Table 4.1). Cynomologus macaque Hexosaminidase expression was also 
detected in the nude mouse brain by immunostaining (Figure 4.4) with an 
antibody against human Hex α-subunit and correlated with measured activity 
levels. Staining revealed numerous cells expressing the enzyme in the thalamus 
and hippocampus of animals in Group 1 (Figure 4.4A, K), Group 2 (Figure 4.4B, 
L), Group 3 (Figure 4.4C, M), and Group 5 (Figure 4.4E, O). 
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Figure 4.2 Total hexosaminidase isozyme activity in athymic nude mouse brain after 
intracranial delivery of AAVrh8 vectors encoding cynomolgus Hexα and Hexβ. Athymic 
nude mice were injected intracranially with 1.32 x 1010 vg of AAVrh8 vectors and Hex activity was 
measured one month post injection. Hex activity was measured using MUG artificial substrate 
recognized by all Hex isoforms (HexA, B, and S) and normalized to baseline enzyme activity in 
naïve nude mouse brain. The brain was divided in coronal blocks for biochemical measurement 
of Hex activity - C1: olfactory bulbs and first 3 mm coronal slice of cerebrum, C2: following 2 mm 
coronal slice of cerebrum, C3: following 3 mm coronal slice of cerebrum which contain injection 
sites, C4: following 2 mm coronal slice of cerebrum, CRBL: cerebellum, BS: brain stem, SC: 
spinal cord). 
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Figure 4.3. HexA and HexS isozyme activity in athymic nude mouse brain after  intracranial 
delivery of AAVrh8 vectors encoding cynomolgus Hexα and Hexβ. Combined HexA and 
HexS activity measured with MUGS substrate, normalized baseline enzyme activity in naïve nude 
mouse brain. The brain was divided in coronal blocks for biochemical measurement of Hex 
activity - C1: olfactory bulbs and first 3 mm coronal slice of cerebrum, C2: following 2 mm coronal 
slice of cerebrum, C3: following 3 mm coronal slice of cerebrum which contain injection sites, C4: 
following 2 mm coronal slice of cerebrum, CRBL: cerebellum, BS: brain stem, SC: spinal cord). 
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Table 4.1 Experimental groups and relative hexosaminidase activity in the injected coronal 
brain block. Treatment groups are shown with corresponding AAVrh8 vectors and average 
hexosaminidase activity determined with MUG and MUGS substrates (Figures 4.2 and 4.3). 
 
 
 
Figure 4.4 NHP hexosaminidase expression in athymic nude mouse brain varies among 
AAVrh8 vectors. Immunofluorescence detection of Hexα expression (green) in the thalamus and 
hippocampus of Group 1 (A, K), Group 2 (B, L), Group 3 (C,M), Group 4 (D,N), Group 5 (E,O), 
Group 6 (F,P), Group 7 (G,Q), Group 8(H,R), Group 9(I,S), and Group 10 (J,T) mice; Nuclei 
counterstained with DAPI (blue) Magnification 40x. 
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Neuropathology in nude mouse brain 
Neuropathological examination of the brains revealed numerous thalamic 
neurons containing eosinophilic granules in Group 1 animals (Figure 4.5A). This 
finding is identical to our observations in monkeys injected with these AAV 
vectors used in Group 1 (Chapter III), but the number of these abnormal neurons 
appears considerably lower in mice than monkeys. This observation was also 
made in Group 2 animals, but the number of abnormal neurons was considerably 
lower than in Group 1 (Figure 4.5B). We also observed abnormal neurons in the 
hippocampus of Group 1 & 2 animals (Figure 4.5K, L). We found no evidence of 
neurons with eosinophilic granules in the brain of any other group. 
 
 
Figure 4.5 Mouse brains expressing highest levels of NHP hexosaminidase protein contain 
eosinophilic neurons. Hematoxylin and eosin stained tissue sections show the presence of 
neurons containing eosinophillic granules (example indicated by white arrows) that correlate with 
cynomolgus Hex expression levels in the hippocampus and thalamus. Group 1 (A, K), Group 2 
(B, L), Group 3 (C,M), Group 4 (D,N), Group 5 (E,O), Group 6 (F,P), Group 7 (G,Q), Group 
8(H,R), Group 9(I,S), and Group 10 (J,T) mice. Magnification 40x. 
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Lower Hexosamindase overexpression results in less gliosis 
 
Increased microglia activation, evaluated with Iba-1 staining, was 
observed in the thalamus and hippocampus in animals injected with the original 
AAVrh8 vector formulation (Figure 4.6A, K) compared to controls (Figure 4.6 H-J; 
R-T). This evidence of microglia activation was localized to the sites where Hexα-
positive cells were detected by immunofluorescence staining (Figure 4.4) with no 
apparent changes in microglia elsewhere in the brain (data not shown). The 
increase in Iba-1 staining in thalamus and hippocampus was considerably milder 
in Groups 2 and 3 (Figure 4.6B-C; L-M), and essentially indistinguishable from 
controls in Groups 4-7 (Figure 4.6D-G; N-Q). 
 
Figure 4.6 Absence of microglial activation in brains injected with AAVrh8 vectors 
expressing lower levels of NHP hexosaminidase. Iba-1 immunostaining showed reduced 
microglia activation in groups expressing lower NHP Hex levels in the hippocampus and 
thalamus. Group 1 (A, K), Group 2 (B, L), Group 3 (C,M), Group 4 (D,N), Group 5 (E,O), Group 6 
(F,P), Group 7 (G,Q), Group 8(H,R), Group 9(I,S), and Group 10 (J,T). Magnification 40x. 
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We also analyzed the brain for evidence of reactive astrogliosis using 
GFAP immunostaining (Figure 4.7). In the thalamus there appeared to be some 
degree of astrogliosis in Groups 1, 2, and 4 (Figure 4.7A-B, D), and mild or 
indistinguishable from controls in Groups 3, and 5-7 (Figure 4.7C, E-G). In the 
hippocampus we only found evidence of reactive astrogliosis in animals injected 
with the original AAVrh8 vector formulation (Figure 4.7K). All others were 
indistinguishable from controls. We found no evidence of astrogliosis in other 
areas of the brain in any of the groups. 
 
Figure 4.7 Absence of astrocyte activation in brains injected with AAVrh8 vectors 
expressing lower levels of NHP hexosaminidase. GFAP immunostaining showed reduced 
numbers of activated astrocytes in groups expressing lower NHP Hex levels in the hippocampus 
and thalamus. Group 1 (A, K), Group 2 (B, L), Group 3 (C,M), Group 4 (D,N), Group 5 (E,O), 
Group 6 (F,P), Group 7 (G,Q), Group 8(H,R), Group 9(I,S), and Group 10 (J,T). Magnification 
40x. 
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Testing new vector designs in primates for Hexosaminidase expression and 
safety 
 
Three of the six new AAVrh8 vector designs (Figure 4.8) were chosen 
from the screen in athymic nude mice that mediated overexpression of 
Hexosaminidase in brain with minimal inflammatory response compared to the 
original AAVrh8 vector. These three AAVrh8 vectors were injected (3.2 x1011 vg) 
into the brain of NHPs (n=2 per cohort) screened for low neutralizing antibody 
titers to AAVrh8. 
 
Figure 4.8 New AAVrh8 vectors selected for further testing in non-human primates. Three 
vectors were chosen from the nude mouse screen (Figure 4.1) to assess toxicity in NHP. 
AAVrh8-CBA-cmHexα/β (cohort 1) contains all elements of our original vector without the 
WPREmut6ΔATG element. AAVrh8-CB-CI-cmHexα/β (cohort 2) is further reduced from cohort 1 by 
the removal of the CMV enhancer. In AAVrh8-P2-CI-cmHexα/β (cohort 3) the CBA or CB 
promoter is replaced with a small weaker promoter sequence. 
 
Clinical outcomes in primates 
 All NHPs tolerated the surgical procedure well with no complications. The 
behavior of all six AAVrh8-injected NHPs remained normal throughout the 90-day 
study. Brain MRI was carried out monthly. Small signal changes at the injection 
sites were documented in two monkeys (295748 and 295709) from cohorts 2 
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(AAVrh8-CB-CI-cmHexα/β) and 3 (AAVrh8-P2-CI-cmHexα/β) from 30 days 
onward. However, there were no significant changes over time (Figure 4.9). In 
one monkey (ID 295851) in cohort 1 there were no signal changes in brain MRIs 
at days 30 and 60 post-injection. However, a signal change was detected in the 
left thalamus at day 90 (Figure 4.9). Despite the appearance of this abnormal 
signal at day 90 the behavior of this monkey remained normal throughout the 
study. 
 
Figure 4.9 T2- and T1-weighted brain MRI sections of AAVrh8 injected non-human 
primates over time. AAVrh8 vectors were co-injected with gadolinium to assess distribution in 
the thalamus, through imaging, immediately after surgery (second row, bright signals). Arrows 
indicate regions of hyperintense signal in the thalamus in three NHPs. 
 
Hexosaminidase activity in primate brain 
 As expected from our studies in athymic nude mice, total Hexosamindase 
activity in thalamic punches was highest in cohort 1 (up to 87-fold above normal), 
and similar (up to 9-fold above normal) in cohorts 2 and 3 (Table 4.2). 
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Table 4.2 Increase in hexosaminidase activity in the thalamus of AAVrh8 injected non-
human primates. Hexosaminidase activity in 3 mm biopsy punches taken from dorsal and 
ventral thalamus of AAVrh8 injected monkeys measured using MUG substrate. Red indicates 
higher activity than normal. 
 
Neuropathology in primate brain 
 Neuropathological evaluation of the brains revealed abundant 
accumulation of intraneuronal eosinophilic material in monkeys in cohort 1 
(Figure 4.10A, black arrow).  Moderate to severe neuronal degeneration (Figure 
4.10A, red arrow) and neuronophagia (Figure 4.10A, purple arrow) was seen in 
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cohort 1 animals. In the left thalamus of one monkey (ID 295851) in cohort 1 
there was severe necrosis with perivascular lymphoeosinophilic encephalitis 3 
mm in diameter that extended 750 µm (Figure 4.10B, C). This lesion 
corresponded to the abnormal MRI signal that became evident in the left 
thalamus of this animal at day 90 (Figure 4.9).  
In cohort 2 there was no accumulation of eosinophilic material and rare 
neuronal degeneration (Figure 4.10D). Focal inflammation of white matter with 
neuronal degeneration and mild multifocal gliosis, most likely associated with 
injection track trauma, was noted in one monkey (ID 295847) as was observed in 
cohort 3 (Figure 4.10F). 
In cohort 3 there was no accumulation of intraneuronal eosinophilic 
material, rare neuronal degeneration (blue arrows) and satellitosis (Figure 
4.10E). In one monkey (ID 295709) there was a focus of perivascular gitter cells 
likely associated with the cannula track (Figure 4.10F). Quantification of 
histopathology in the thalamus of low (cohort 3) and high (cohort 1) expressing 
animals can be found in Appendix B. 
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Figure 4.10 Neuropathological findings in the thalamus of AAVrh8 injected non-human 
primates. H&E staining indicating the presence of granular eosinophillic neurons in the thalamus 
of injected animals in cohort 1 (A, black arrows), neuronal degeneration (red arrow), and 
neuronophagia (purple arrow). In the left thalamus of animal 295851 of cohort 1 severe focal, 
necrotizing, perivascular, and lymphoeosinophilic encephalitis was observed (B, C). In cohort 2 
animals there was no accumulation of eosinophilic material in neurons, rare neuronal 
degeneration, and mild multifocal gliosis likely due to injection trauma (D). In cohort 3 there was 
only minimal neuronal degeneration in the thalamus likely due to injection trauma (E). One animal 
in cohort 3 had the presence of perivascular gitter cells likely in the vicinity of the injection track 
(F). Magnification 10x. 
 
Testing therapeutic efficacy and defining a new minimal effective dose of 
AAVrh8-CB-CI-mHexα/β in Sandhoff disease mouse model 
 
 For short-term biochemical analysis of the effect in CNS GM2 ganglioside 
content, SD mice were infused with AAVrh8-CB-CI-mHexα/β vector formulation 
encoding mouse Hexα/β (mHexα/β) subunits at two doses, 4.68 x 109 vg and 
2.34 x 1010 vg and compared to the original AAVrh8 vector (AAVrh8-CBA-
mHexα/β-WPREmut6ΔATG) injected at 4.68 x 109 vg, the dose previously shown to 
have a significant therapeutic effect (Chapter III). GM2 ganglioside content was 
significantly lower in the cerebrum of SD mice injected with either dose of 
AAVrh8-CB-CI-mHexα/β vector compared to PBS-injected SD mice, and the 
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92% reduction observed for the highest dose (2.34x1010 vg) of AAVrh8-CB-CI-
mHexα/β vector was comparable to that documented in SD mice injected with 
the original AAVrh8 vector (97%) (Figure 4.11A). We also observed significant 
reduction in GM2 ganglioside content in cerebellum and brainstem of SD mice 
injected with AAVrh8-CB-CI-mHexα/β vector compared to PBS-injected SD mice, 
however, to a lesser extent than the original AAVrh8 vector. As expected the 
degree of GM2 reduction in the CNS of SD mice injected with AAVrh8-CB-CI-
mHexα/β vector was dose dependent (Figure 4.11A). Hexosaminidase activity in 
the brain of SD mice treated with AAVrh8-CB-CI-mHexα/β vector was dose 
dependent and lower than the original AAVrh8 vector by 7-43 fold, but 
nonetheless 2-12 fold above normal (Figure 4.11B). 
 Another set of SD mice (n=8) was injected with 2.34 x 1010 vg AAVrh8-
CB-CI-mHexα/β to test therapeutic efficacy using survival to 5 months of age 
(one month past the median survival of untreated SD mice) as outcome 
measure. The majority of AAV-treated SD mice (6 of 8) survived to 5 months of 
age. However, only 2/6 animals appeared asymptomatic at 5 months (Figure 
4.11C).  The remaining four mice presented with varying degrees of hind limb 
impairment or weakness.  The hind limb impairment may be explained by the 
more modest reduction in spinal cord GM2 ganglioside content with the new 
AAVrh8 vector formulation compared to the original CBA vector (Figure 4.11A, 
35% vs. 70%). 
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Figure 4.11 Intracranial injection of AAVrh8-CB-CI-mHexα/β vector reduces GM2 
ganglioside storage in CNS with a concomitant increase in hexosaminidase activity leads 
to improved survival of Sandhoff disease mice. SD mice received intracranial injection of 
AAVrh8-CB-CI-mHexα/β vector at total doses of 4.68 x 109 vg or 2.34 x 1010 vg, or of original 
vector (4.68 x 109 vg), or PBS. A) GM2 ganglioside content measured by LC–MS/MS in CNS 8 
weeks after injection. B) Cerebrum hexosaminidase activity measured using MUG substrate 8 
weeks after injection. Dashed line indicates average activity of untreated wild type animals. 
Results are shown as mean ± SD, Tukey's multiple comparisons test, * (P ≤ 0.05), ** (P ≤ 0.01), 
*** (P ≤ 0.001), **** (P ≤ 0.0001), n=4 PBS, n=4 original CBA-mHexα/β, n=6 2.34 x 1010 vg CB-
CI-mHexα/β and 4.68 x 109 vg CB-CI-mHexα/β. n.d. (not detected) C) Survival and symptom 
presentation of (5 month study endpoint) of Sandhoff disease mice injected with 2.34 x 1010 vg of 
AAVrh8-CB-CI-mHexα/β (n=8). Median survival of untreated Sandhoff disease mice was 125.5 
days (n=6). 
 
In order to improve the effect on GM2 ganglioside storage in the spinal 
cord and cerebellum we increased the dose delivered to CSF via the lateral 
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ventricles while maintaining the thalamic dose (1.17 x 1010 vg) constant. SD mice 
were injected with increasing CSF doses of AAVrh8-CB-CI-mHexα/β - 1.17 x 
1010 vg, 2.34 x 1010 vg, 5.85 x 1010 vg, 5.00 x 1011 vg (n=3 per cohort). The 
reduction in GM2 ganglioside content in the spinal cord (Figure 4.12A) and 
cerebellum (Figure 4.12B) at one month after injection was dose dependent with 
the highest dose (5.2x1011 vg total) showing an effect similar to the original 
AAVrh8 vector injected at 4.68 x 109 vg. 
 
Figure 4.12  Increasing doses of CSF delivered AAVrh8-CB-CI-mHexα/β vector further 
reduce GM2 ganglioside storage in spinal cord and cerebellum. SD mice were injected with 
1.17 x 1010 vg of AAVrh8-CB-CI-mHexα/β into the thalamus with increasing CSF doses (1.17 x 
1010 vg, 2.34 x 1010 vg, 5.85 x 1010 vg, 5.00 x 1011 vg). Four weeks after injection GM2 
ganglioside content measured by LC–MS/MS in spinal cord (A) and cerebellum (B). Results are 
shown as mean ± SD, Dunnet’s multiple comparisons tests* (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 
0.001), n=3. 
 
Scaling up AArh8 doses from mouse to monkey to humans per kg of brain 
weight (Table 10.3) would require 1.02 x 1015 vg using our highest ventricular 
dose. Given the feasibility of manufacturing enough AAVrh8 to move forward 
clinically we believe 3.51 x 1010 vg in mice (~7.02 x 1013 vg in humans) shows 
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sufficient evidence of therapeutic benefit and safety to begin further IND-enabling 
studies in SD mice and non-human primates. 
 
Table 4.3 Dosing scale from mouse to monkey to human. AAV doses corresponding to the 
brain weight of mouse, monkey, and humans,168 distributed between thalami and lateral ventricle. 
Thalamus dose is divided between left and right sides.  
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CHAPTER V – DISCUSSION 
Direct CNS administration of AAVrh8 vectors encoding for mouse β-N-
acetylhexosaminidase subunits is well tolerated and leads to long-term survival 
as well as prolonged motor performance of treated Sandhoff disease mice. 
Furthermore, in addition to bilateral thalamic injections, a single injection into the 
lateral ventricle is just as efficacious as bilateral deep cerebellar nuclei injections. 
Targeting the lateral ventricle and avoiding cerebellar injections may ease clinical 
translation. Widespread enzyme expression and therapeutic benefit has also 
been shown in Sandhoff disease cats and Tay-Sachs disease sheep using this 
therapeutic strategy encoding for species-specific subunits.14, 151, 153 Despite 
treated Sandhoff disease mice living a maximum of 666 days, euthanasia was 
usually required due to hind limb ataxia and weakness. These findings could be 
the result of insufficient Hex enzyme expression in the spinal cord. Although 
there was great reduction of GM2 ganglioside storage in the spinal cord, enzyme 
expression was lower than in wild type levels as it was undetected using the 
MUGS substrate.  This may be improved upon by increasing ICV dose and 
volumes, as was done in the Sandhoff disease mice treated with our new 
AAVrh8-CB-CI-mHexα/β vector in Chapter IV (Figure 4.12). 
Production of Hex through direct thalamic and ventricular delivery of 
AAVrh8 vectors encoding species-specific subunits proved to be toxic in normal 
NHPs, probably due to overexpression. The severe neurological symptoms that 
manifested over time were surprising given the demonstrated efficacy and safety 
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of bilateral injections of AAV-Hex vectors (AAV1, AAV2, and AAVrh8) in normal 
and GM2 affected disease mice, cats, and sheep.14, 15, 106, 150, 151, 153 The absence 
of neuropathology elsewhere in the central nervous system (CNS) suggests that 
delivery of AAVrh8-Hex vectors into cerebral spinal fluid through the cerebral 
lateral ventricles is safe. 
The most likely explanation for the neurologic deterioration is the 
extensive neuronal loss in the thalamus, revealed by MRI imaging and 
neuropathological examination of the NHP brains injected with AAVrh8-
cmHexα/β. Unlike the severe histological findings documented here, a prior study 
in NHPs injected with an AAV2 vector expressing human acid sphingomyelinase 
in the thalamus and brainstem also developed severe neurological symptoms but 
with no apparent neuronal loss. Instead there was robust infiltration of injected 
brain structures with inflammatory cells.169 
Several lines of evidence in the present study suggest the 
neurodegenerative process triggered by thalamic injection of AAVrh8-cmHexα/β 
vectors in normal NHPs is unlikely to have been caused by an immunological 
response. The human and cynomolgus macaque hexosamindase α- and β-
subunits differ by 11 and 23 amino acids, respectively (Figures 5.1 and 5.2). 
Intracranial injection of AAV vectors encoding non-self-proteins in NHPs and 
other species has been shown to trigger strong immune responses resulting in 
extensive neuronal loss. In addition to the antigenic nature of the transgene, the 
AAV capsid tropism to antigen presenting cells in the brain may also be a 
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contributing factor.170, 171 Moreover, as patients afflicted with lysosomal storage 
diseases treated by enzyme replacement therapy often develop antibodies to 
recombinant human proteins,172, 173 we considered the differences in Hex 
subunits between species a significant factor that could confound interpretation 
of the results. As such, the AAVrh8-Hex vectors encoded cynomolgus macaque 
hexosamindase α- and β-subunits, which would make it unlikely that neuronal 
loss was caused by an adaptive immune response to the transgenes. The 
presence of large numbers of transduced neurons in the thalamus near areas of 
heavy neuronal loss further supports the notion of a non-immune mechanism. In 
addition, inflammatory cells in thalamus were mostly of the macrophage lineage 
(CD68+) with very few CD3+ T-cells only found near some blood vessels. These 
findings suggest that the inflammatory cell infiltration was likely secondary to a 
primary neurodegenerative insult. Also, we found no evidence of antibodies to 
HexA at the endpoint, although this finding has a caveat that the ELISA assay 
was based on commercially available human Hex, and thus it is possible that it 
failed to detect antibodies to NHP specific epitopes.  
Despite having low or absent neutralizing antibodies to AAVrh8 (titer 
<1:10) prior to injection, all NHPs injected with AAVrh8 vectors had high anti-
capsid antibody titers at the endpoint. However, a humoral response to the 
capsid is unlikely to have a significant contribution to the neuronal loss as control 
NHPs injected with the transgene-empty AAVrh8 vector showed no evidence of 
neuropathology beyond that associated with the needle track. Moreover, 
	 85 
previous studies have reported the presence of high anti-AAV antibody titers 
after intracranial delivery in NHPs with no apparent adverse effects.156, 157 
Therefore, this study highlights the safety of an AAV vector, but also uncovers 
the toxicity that can be associated with a biochemical mechanism, such as 
overexpression, that is not related to AAV vector or transgene immunogenicity. 
 Despite extensive neuronal loss, Hex activity in the thalamus of NHP 
injected with AAVrh8-cmHexα/β vector was >100 fold above normal. These high 
Hex expression levels appear to be driven by the remaining transduced neurons 
laden with eosinophilic granules filled with Hex as indicated by co-
immunofluorescence staining with antibodies to Hex α- and β-subunits. Neurons 
with identical intracellular features were also found in the thalamus of long-lived 
cats treated with AAVrh8 vectors encoding feline Hex subunits, but with no 
evidence of neuronal loss or neurological deficits.14 Transgenic mice 
overexpressing lysosomal beta-glucuronidase (GUSB) also displayed 
eosinophilic granules in different cell types, and brain expression levels were 
~100-700 fold above normal with no apparent neurological deficits. This indicates 
that massive overexpression of at least GUSB in neurons is well tolerated.174 
However, there are fundamental differences between transgenesis and AAV 
mediated de novo overexpression, namely developmental adaptation of cellular 
pathways to high-level expression of a lysosomal enzyme. Also, tissue level 
activity in transgenic mice is likely the result of relatively uniform enzyme activity 
in most cells in the tissue. On the other hand, the efficiency of AAV gene delivery 
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to the brain by intraparenchymal injection is far from achieving transduction of all 
cells in a particular structure and thus the measured activities are the result of 
enzyme expression in a subset of cells. The >100 fold above normal HexA levels 
in the thalamus of AAVrh8 injected NHPs at endpoint appeared to be produced 
by a relatively small number of neurons, and thus it is likely that activities in those 
cells are considerably higher than the average measured in tissue punches but 
are still compatible with survival. It seems reasonable to postulate that HexA 
expression crossed an unknown threshold in some cells that triggered a 
neurodegenerative process. A possible mechanism is that continuous high-level 
expression of HexA overtaxes the protein folding capacity in some AAV 
transduced neurons leading to a chronic unfolded protein response that 
ultimately results in cell death.175 It has been demonstrated in other fields that 
vector mediated over expression of RNAi, with the use of strong promoters such 
as U6, leads to cellular toxicity due to saturation of the miRNA pathway.176 The 
exact limit of overexpression tolerated by neurons is unknown, but the notion that 
lysosomal enzymes can be expressed at any level with no consequences to 
genetically modified cells should be reconsidered, although we are unable to 
exclude the possibility that these adverse events are HexA specific. An example 
of overexpression-associated toxicity of a lysosomal enzyme in a particular target 
cell type is that described for ex vivo lentivirus gene therapy in Krabbe disease 
where galactocerebrosidase proved to be toxic to hematopoietic stem cells but 
not to their progeny.177 This has not been documented for other lysosomal 
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enzymes where this ex vivo strategy has been successful for storage diseases 
such as metachromatic leukodystrophy.53, 54 A recent study using systemic 
delivery of AAV9 encoding another lysosomal enzyme, α-N-
acetylglucosaminidase, to treat mucopolysaccharidosis (MPS) IIIB resulted in 
liver toxicity associated with transgene overexpression in wild type but not MPS 
IIIB mice.178 Presently, we are unable to exclude the possibility that toxicity is the 
result of unique properties of cynomolgus macaque hexosaminidase subunits. 
However, we have also seen similar histopathology and Hex overexpression that 
was demonstrated in Chapter IV, when we inject nude mice with AAVrh8 vectors 
that encode for the human transgene as well (data not shown). Further studies 
with hexosaminidases from different species will be necessary to address this 
possibility. 
The reasons for the difference in outcomes between NHPs and normal 
cats injected with AAVrh8 vectors carrying the same expression elements at 
comparable doses are unknown. It is possible the CBA promoter and/or WPRE in 
the transgene expression cassette have different potencies across species, and 
also that AAVrh8 transduces NHP cells more efficiently given that it was cloned 
from rhesus macaque tissues.179 Other AAV serotypes that efficiently transduce 
the CNS could also be explored. Alternatively, there could be species-specific 
thresholds of sensitivity for overexpression. The 3x1012 vg dose tested in NHP 
was based on a prior study 153 where GM2 cats were treated with 1.1x1012 vg of 
AAVrh8 vector delivered bilaterally to the thalamus and CSF via the lateral 
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ventricle. The dose/brain weight is comparable at 5.3x1013 vg/kg considering 
average brain weights of 60.4±5.5 g and 20.9±1.6 g in young cynomolgus 
macaques and cats, respectively. An important aspect to consider is that the 
thalamic dose in cats was delivered in a columnar fashion where the needle was 
raised 0.15 cm after each 10-20 µL bolus, while in NHP we used convection 
enhanced delivery in a single site in the thalamus. The two infusion techniques 
likely generate different patterns of AAV vector distribution in the thalamus and 
possibly transduction efficiency that might be reflected in differences in AAV 
genome copy number per cell. Nonetheless a 30-fold reduction in AAV vector 
dose in NHP was insufficient to prevent toxicity in NHP. This suggests that 
differences in infusion technique and ultimately AAV distribution in thalamus are 
unlikely to explain the surprising difference in outcomes in monkeys and cats. 
The degree of neuronal loss documented in monkeys prevents a meaningful 
comparison of AAV vector genome content in the thalamus between the two 
species and others, as it is impossible to know how much of the initial dose has 
been lost in monkeys due to toxicity. Presently there is no information on the 
degree of enzyme overexpression in individual AAV transduced cells (neurons) in 
the brain that is compatible with long-term safety and efficacy. The difference in 
safety outcomes across and within species raises concerns about the predictive 
value of pre-clinical dose ranging and safety studies when translating AAV gene 
therapies from animals to humans.  
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Prior studies assessing the safety of multisite intracranial delivery of 
AAVrh10 vectors in NHPs reported no serious adverse events.157, 180 However, 
neuropathological examination revealed neuronal loss at the injection sites, but 
because the studies were carried out with AAVrh10 vectors encoding human 
enzymes, it is not possible to distinguish between an immunologically driven 
effect and toxicity due to overexpression as documented here. The absence of 
neurological side effects in those studies may simply be due to the small injection 
volumes per site (10 µL) in non-motor cortical regions where the effect of 
neuronal loss in small numbers may not be easily detectable. It is also possible 
that thalamic neurons, or a subdivision of the thalamus, may be more sensitive. 
The mechanistic basis for the neuronal loss/spongiosis observed in those studies 
has different implications for the success in translation of these multisite 
approaches to patients. Clinical trials have been initiated with AAVrh10 vectors 
tested in NHPs and the outcomes in patients will ultimately reveal the safety and 
efficacy of the multisite delivery approach (NCT01801709). If successful, this 
multisite approach may be a better strategy to treat GM2 gangliosidoses as well. 
It could also be a strategy to overcome a decrease in vector load or lower 
expression levels in humans while still maintaining widespread distribution of 
enzyme. However, this superficial multisite approach may not treat deep brain 
structures, such as the thalamus, which in GM2 gangliosidoses patients are 
compromised as indicated by alterations in both CT and MRI (T1 and T2 
weighted) imaging.181, 182 Aside from the safety differences among species as 
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demonstrated here, the differences in brain sizes and CSF flow from mice to 
cats, to primates, and to humans may all play a role in vector and enzyme 
distribution and subsequent expression levels.168, 183 We assume that the brain of 
a child less than 1 year of age will weigh approximately 500 g.168 A comparable 
infusion volume will require the infusion of approximately 3 mL in each thalamus. 
However, we think such volumes would be an unacceptable risk to the patients 
and would require a delivery time of greater than 13 hours, assuming a delivery 
rate of 2 µl/min and 3.2 mL in the thalamus distributed over 2 sites (1.6 mL/site). 
Therefore, we may initially have to limit infusion volumes in patients and develop 
strategies to safely increase infusion rates. 
Since dose reduction was not enough to overcome this toxicity other 
strategies to reduce Hex expression while maintaining AAV vector dose, and 
therefore vector and enzyme distribution was employed. Six new AAVrh8 vector 
designs were created by the removal and/or replacement of promoters and other 
transcriptional elements, which achieved the predicted gradient of Hex 
expression.  A vector screen in mice revealed three new formulations with 
reduced enzyme expression and low toxicity compared to our original vector. 
Testing of AAVrh8-CBA-cmHexα/β, AAVrh8-CB-CI-cmHexα/β, and AAVrh8-P2-
CI-cmHexα/β in primates revealed AAVrh8-CBA-cmHexα/β to have the highest 
Hex expression, but showed toxicity in 1 out of 4 injection sites. It is possible that 
the exact placement of the cannula in the brain parenchyma could impact viral 
vector distribution and therefore transduction efficiency, affecting expression 
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levels which then leads to toxicity. AAVrh8-CB-CI-cmHexα/β and AAVrh8-P2-CI-
cmHexα/β had similar expression levels of Hex to each other and showed 
minimal toxicity. Since vector elements of AAVrh8-CB-CI-cmHexα/β are most 
similar to original formulation and are widely used in the field, we believe it will be 
the best candidate to move forward to the clinic. In comparison to our original 
formulation, AAVrh8-CB-CI-cmHexα/β does not contain the CMV enhancer or the 
WPREmut6rATG element. Reduction of expression through alterations of vector 
design does have negative consequences on therapeutic efficacy when delivered 
at similar doses to our original vector in Sandhoff disease mice.  We were able to 
successfully treat the cerebrum comparably to our original vector by increasing 
vector dose 2-5 fold.  However, treating other areas of the CNS as well as with 
our original vector, particularly in the spinal cord, requires large increases in the 
vector dose and volumes delivered to the lateral ventricle. It may be possible to 
test alternative routes of vector delivery to treat the spinal cord such as cisterna 
magna or intrathecal delivery, which has proven successful in other lysosomal 
storage and CNS disorders.93 
Overexpression and secretion of lysosomal enzymes from genetically 
modified cells is the fundamental tenet of the current ex vivo and in vivo gene 
therapy approaches for lysosomal storage diseases. Though the exact tolerability 
limits for lysosomal enzyme overexpression in neurons is unknown and may vary 
across enzymes, the notion that these proteins can be safely expressed at any 
level with no consequences should be evaluated carefully. 
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Future Directions 
 Now that we have shown safety and efficacy with our newly optimized 
AAVrh8-Hexα/β vectors, formal IND-enabling studies for safety and efficacy will 
need to be performed in Sandhoff mice along with a formal IND-enabling toxicity 
study in primates in order to move this therapy forward to clinical trials. These 
studies will be done using doses flanking and including our newly defined 
minimum effective dose (3.51 x 1010 vg in mice, 4.56 x 1012 in monkeys, and 7.02 
x 1013 vg in humans). A concern with translating this therapy to the clinic will be 
the possibility of a patient’s immune response to the AAV capsid and transgene 
product. Ideally patients chosen for the trial will not have preexisting antibodies 
towards AAVrh8. In addition, the initial patients enrolled in the study will ideally 
be those with juvenile form of TSD or SD since these patients will have some 
endogenous Hex expression, albeit a mutated form. Clinical trials using AAV8 to 
treat Hemophilia B (NCT00979238) have shown a short course of glucocorticoids 
can limit immune response to the capsid allowing for long-term transgene 
expression.184 
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Monkey      1   MASSRLWFSLLLAAAFAGRATALWPWPQNIQTSDQRYVLYPNNFQFQYDISSAAQPGCSV 60 
Human           MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSV 
 
Monkey      61  LDEAFQRYRDLLFGSGSWPRPYRTGKRHTPEKNVLVVSVVTPGCNQLPTLESVENYTLTI 120 
Human           LDEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTI 
 
Monkey      121 NDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHY 180 
Human           NDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHY 
 
Monkey      181 LPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVK 240 
Human           LPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVK 
 
Monkey      241 EVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEF 300 
Human           EVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEF 
 
Monkey      301 MSTFFLEISSVFPDFYLHLGGDEVDFTCWKSNPDIQDFMRKKGFGEDFKQLESFYIQTLL 360 
Human           MSTFFLEVSSVFPDFYLHLGGDEVDFTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLL 
 
Monkey      361 DIVSSYGKGYVVWQEVFDNKVKIRPDTIIQVWREEIPVNYMKELELVTKAGFRALLSAPW 420 
Human           DIVSSYGKGYVVWQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSAPW 
 
Monkey      421 YLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAV 480 
Human           YLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAV 
 
Monkey      481 AERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLHVGYCEQEFEQT 529 
Human           AERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLNVGFCEQEFEQT 
 
Figure 5.1 β-N-acetylhexosaminidase α-subunit amino acid sequences. Amino acid 
sequence alignment of monkey (cynomolgus macaque) and human. Differences highlighted in 
yellow. 
 
Monkey      1   MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEATRAPGVSAARGPALWPLP  60 
Human           MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEAARAPSVSAKPGPALWPLP 
 
Monkey      61  LSVKMTPNLLHLAPENFYISHSPNSTAGPSCTLLEEAFRRYHSYIFGFYKWDHEPAKSQA 120 
Human           LSVKMTPNLLHLAPENFYISHSPNSTAGPSCTLLEEAFRRYHGYIFGFYKWHHEPAEFQA 
 
Monkey     121  TAQLQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVY 180 
Human           KTQVQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVY 
 
Monkey      181 QDSCGTFTINESTIIDSPRFPHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLHWHIVD 240 
Human           QDSYGTFTINESTIIDSPRFSHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLHWHIVD 
 
Monkey      241 DQSFPYQSIAFPELSNKGSYSLSHVYTPNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGK 300 
Human           DQSFPYQSITFPELSNKGSYSLSHVYTPNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGK 
 
Monkey      301 GQKDLLTPCYSRQNKLDSFGPINPTLNTTYSFLTTFFKEISEVFPDQFIHLGGDEVEFKC 360 
Human           GQKDLLTPCYSRQNKLDSFGPINPTLNTTYSFLTTFFKEISEVFPDQFIHLGGDEVEFKC 
 
Monkey      361 WESNPKIQDFMKQKGFGKDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKVKLAPGTI 420 
Human           WESNPKIQDFMRQKGFGTDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKAKLAPGTI 
 
Monkey      421 VEVWKDNAYPEELSKVTASGFPVILSAPWYLDLISYGQDWRKYYKVEPLDFGGTREQKQL 480 
Human           VEVWKDSAYPEELSRVTASGFPVILSAPWYLDLISYGQDWRKYYKVEPLDFGGTQKQKQL 
 
Monkey      481 FIGGEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDGAYDRLTRHRCRMVERG 540 
Human           FIGGEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDDAYDRLTRHRCRMVERG  
 
Monkey      541 IAAQPLYAGYCNHENV 556 
Human           IAAQPLYAGYCNHENM 
 
Figure 5.2 β-N-acetylhexosaminidase β-subunit amino acid sequences. Amino acid 
sequence alignment of monkey (cynomolgus macaque) and human. Differences highlighted in 
yellow. 
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APPENDIX A 
SEQUENCES OF PROMOTERS AND OTHER TRANSCRIPTIONAL 
ELEMENTS 
 
Sequence of CMV enhancer (CMVEn): 
       1 CTGAATTCGG TACCCTAGTT ATTAATAGTA ATCAATTACG GGGTCATTAG TTCATAGCCC  
      61 ATATATGGAG TTCCGCGTTA CATAACTTAC GGTAAATGGC CCGCCTGGCT GACCGCCCAA  
     121 CGACCCCCGC CCATTGACGT CAATAATGAC GTATGTTCCC ATAGTAACGC CAATAGGGAC  
     181 TTTCCATTGA CGTCAATGGG TGGACTATTT ACGGTAAACT GCCCACTTGG CAGTACATCA  
     241 AGTGTATCAT ATGCCAAGTA CGCCCCCTAT TGACGTCAAT GACGGTAAAT GGCCCGCCTG  
     301 GCATTATGCC CAGTACATGA CCTTATGGGA CTTTCCTACT TGGCAGTACA TCTACGTATT  
     361 AGTCATCGCT ATTAC 
 
Sequence of CB promoter: 
       1 CATGGTCGAG GTGAGCCCCA CGTTCTGCTT CACTCTCCCC ATCTCCCCCC CCTCCCCACC  
      61 CCCAATTTTG TATTTATTTA TTTTTTAATT ATTTTGTGCA GCGATGGGGG CGGGGGGGGG  
     121 GGGGGGGCGC GCGCCAGGCG GGGCGGGGCG GGGCGAGGGG CGGGGCGGGG CGAGGCGGAG  
     181 AGGTGCGGCG GCAGCCAATC AGAGCGGCGC GCTCCGAAAG TTTCCTTTTA TGGCGAGGCG  
     241 GCGGCGGCGG CGGCCCTATA AAAAGCGAAG CGCGCGGCGG GCG 
 
Sequence of chimeric intron (CI): 
       1 GTGAGCGGGC GGGACGGCCC TTCTCCTCCG GGCTGTAATT AGCGCTTGGT TTAATGACGG  
      61 CTTGTTTCTT TTCTGTGGCT GCGTGAAAGC CTTGAGGGGC TCCGGGAGCT AGAGCCTCTG  
     121 CTAACCATGT TCATGCCTTC TTCTTTTTCC TACAGCTCCT GGGCAACGTG CTGGTTATTG  
     181 TGCTGTCTCA TCATTTTGGC AAAGAATTCC TCGAAGATCC GAAGGGGTTC AGGAGTCGCT  
     241 GCGACGCTGC CTTCGCCCCG TGCCCCGCTC CGCCGCCGCC TCGCGCCGCC CGCCCCGGCT  
     301 CTGACTGACC GCGTTACTCC CACAG 
 
Sequence of modified WPRE: 
       1 GATAATCAAC CTCTGGATTA CAAAATTTGT GAAAGATTGA CTGGTATTCT TAACTTTGTT  
      61 GCTCCTTTTA CGCTTTGTGG ATACGCTGCT TTATTGCCTT TGTATCTTGC TATTGCTTCC  
     121 CGTTTGGCTT TCATTTTCTC CTCCTTGTAT AAATCCTGGT TGCTGTCTCT TTTTGAGGAG  
     181 TTGTGGCCCG TTGTCAGGCA ACGTGGCGTG GTGTGCACTG TGTTTGCTGA CGCAACCCCC  
     241 ACTGGTTGGG GCATTGCCAC CACCTGTCAG CTCCTTTCCG GGACTTTCGC TTTCCCCCTC  
     301 CCTATTGCCA CGGCGGAACT CATCGCCGCC TGCCTTGCCC GCTGCTGGAC AGGGGCTCGG  
     361 CTGTTGGGCA CTGACAATTC CGTGGTGTTG TCGGGGAAAT CATCGTCCTT TCCTTGGCTG  
     421 CTCGCCTGTG TTGCCACCTG GATTCTGCGC GGGACGTCCT TCTGCTACGT CCCTTCGGCC  
     481 CTCAATCCAG CGGACCTTCC TTCCCGCGGC CTGCTGCCGG CTCTGCGGCC TCTTCCGCGT  
     541 CTTCGCCTTC GCCCTCAGAC GAGTCGGATC TCCCTTTGGG CCGCCTCCCC GCATCGGACT  
     601 AG 
 
Sequence of P2 promoter: 
 
       1 CTGGAGCCGG TGTCAGGTTG CTCCGGTAAC GGTGACGTGC ACGCGTGGGC GGAGCCATCA  
      61 CGCAGGTTGC TATATAAGCA GAGCTCGTTT AGTGAACCGT CAGA 
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APPENDIX B 
HISTOPATHOLOGIC CHANGES SEEN IN SHORT TERM PRE-CLINICAL 
SAFETY FOR GENE THERAPY FOR TAY-SACHS AND SANDHOFF DISEASE 
 
Keiko Petrosky 
October 30, 2014   
Division of Comparative Pathology New England Primate Research Center 
Harvard Medical School Southborough, MA  
 
Serial sections (150 microns apart) were taken of the right and left thalamus of 
animals in high expressors (Cohort 1, n = 2) and low expressors (Cohort 3, n = 2) 
for analysis. Unfortunatley, embedding and cutting of cohort 2 resulted in poor 
quality sections and could not be used for quantitative analysis. However, 
qualitative analysis of cohort 2 and cohort 3 indicate similar levels of 
histopathological changes. 
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